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Zymosan can activate the lymphocytes and macrophages o f 
mice. Tumor necrosis factor (TNF) can be produced in zymosan-
primed Ehrlich ascites tumor (EAT) bearing mice with subsequent 
challenge with lipopolysaccharide (LPS). The in vivo production 
of TNF on the treatment of EAT bearing mice was studied. The 
optimal procedures are as follows on day 0, EAT cells are 
inoculated intraperitoneally into each mouse; on day 1, 2 - 5 mg 
zymosan is injected intraperitoneally into each mouse; on day 7, 
25 ug LPS is injected intravenously into each mouse. However, 
the rate of mortality from endotoxin shock is high in these mice 
during this treatment. The endotoxin shock induced in normal or 
tumor-bearing mice can be minimized by combined administration 
of sulindac and manno~eptulose. 
TNF titres in sera of EAT bearing mice have been found to 
be lower than that of non-EAT bearing mice under this treatment. 
Large burden of EAT increases the mortality of mlce after the 
injection of LPS. Moreover, the effectiveness of anti-tumor 
I 
effects of TNF are larger i~ mice bearing smaller numbers of 
turnor cells. 
The proliferation of'- EAT cells in mice has been found to 
be suppressed by the direct effect of in vivo production of TNF. 
It is because TNF being induced can pass into the peritoneal 
cav{ty of EAT-bearing mic~. This TNF can significantly inhibit 
DNA and protein synthesis of EAT cells in vivo, but cannot 
change glucose uptake rate of EAT cells. 
i 
Abs t ract 
The combined treatments of in vivo production of TNF with 
hyperthermia, methotrexate (MTX), polyriboinosinic-
polyribocytidylic acid (poly I·C) and N-(phosphonacetyl)-L-
aspartate (PALA) on EAT-bearing mlce have also been carried out. 
The combined treatments have been found to have an additive 
effect on the suppression of EAT cell numbers. Combined 
treatments of ~n vivo production of TNF and hyperthermia can 
prolong the survival rate of EAT-bearing mice while comparing 
with that of using only one treatment. 
LPS injections to zymosan-primed normal mice or EAT-
bearing mice induce decreases of body temperature, body weight 
and blood glucose of . the hosts. LPS injections to zymosan-
primed normal rat induce decreases of body temperature and body 
weight as well as lncreases of rate of lipolysis of . adipocytes 
of the hosts. Sulindac and mannoheptulose have little effect in 
alleviating the side effects of LPS on body temperature and body 
weight of these experimental animals 
Acknowledgemen ts 
ACKNOWLEDGEMENTS 
I would like to . express my sincere gratitude to 
Dr. Ko P. Fung for his valuable advice, deliberative criticism 
and stimulating discussions throughout the course of my M.Phil. 
programme. I am also greatly indebted to Professor T. B. Lo, 
Dr. Y. M. Choy and Dr. T. B. Ng for their willingness to 
serve as members of my thesis committee. 
I am very grateful to my family for their support and 
encouragement. Thanks also go to my colleagues in the 
laboratory Room 151 of Science Centre. 
The generous supply of human recornbinant turnor necrosis 
factor by Genetech. Inc. (U.S.A.) is greatly appreciated. This 
































Bacillus Camette Guerin 
Bovineserum albumin 






Ehrlich ascites tumor 
Ethylenediamine-tetraacetic acid 
Epinephrine-(-) 
Enzyme-linked immunosorbent assay 






Heat inactivated fetal calf serum 



































Maximum tolerated dose 
Methotrexate • 
Abbre viation 
Non-steroidal anti-inflammatory drugs 
Optical density at 540 nm 
N-(phosphonacetyl)-L-aspartate 









Sulindac and mannoheptulose-treated 
Trichloroacetic acid 
Tumor necrosis factor/Cachectin 




TABLE OF CONTENTS 
ABSTRACT 1 
ACKNOWLEDGEMENTS ii i 
ABBREVIATIONS lV 
CHAPTER 
1. INTRODUCTION: An overview of Turnor Necrosis Factor 
(TNF) 
1. The discovery of turnor necrosis factor (TNF) 1 
2. Production of turnor necrosis factor 3 
3. Physiochemical properties of TNF 5 
4. Biological activities of TNF on various cells 
in the mammal 8 
5. Mechanisms of anti-turnor action of TNF 12 
6. Clinical studies of Hr-TNF 19 
2. AIM OF INVESTIGATION 23 
3. MATERIALS AND METHODS 
A. MATERIALS 26 
B. METHODS 
1. Preparation of Reagents i 30 
2. Cell Culture 31 
3. Lyrnphocytes proliferation 32 
4. In vitro production of tumor necrosis factor 
(TNF) by peritoneal macrophages of ICR mige 33 
5. Production of TNF in animals 34 
6. Determination of TNF titre 35 
7. Determination of TNF containing serum titre on EAT 
in vitro 
8. Mortality determination of mice 
9. 3H-Thymidine, 3H-uridine, 14C-leucine 
incorporation 
10. Glucose uptake determination 
11. Whole body hyperthermic treatment of 
EAT bearing mice 
12. Lipolysis assay 
13. Statistical analysis 
4. IN VIVO PRODUCTION OF TUMOR NECROSIS FACTOR USING 





5. SIDE EFFECTS DURING IN VIVO PRODUCTION OF TUMOR 
















6. MODIFIED PROCEDURE FOR THE IN VIVO PRODUCTION OF TUMOR 
NECROSIS FACTOR FOR THE TREATMENT OF EHRLICH ASC ITES 





7. COMBINED TREATMENTS OF IN VIVO PRODUCTION OF TUMOR 
NECROSIS FACTOR (TNF) WITH HYPERTHERMIA, METHOTREXATE 
(MTX), POLYRIBOINOSINIC-POLYRIBOCYTIDYLIC ACID 
(POLY IoC), N-(PHOSPHONACETYL)-L-ASPARTATE (PALA) 





8. EFFECTS OF IN VIVO PRODUCTION OF TUMOR NECROSIS FACTOR 





9. SIDE EFFECTS OF TUMOR NECROSIS FACTOR AND 





10. CONCLUSION AND OUTLOOK 174 
BIBLIOGRAPHY 181 
TUMOR NECROSIS FACTOR 
CHAPTER 1 
INTRODUCTION 
1. The discovery of turnor necrosis factor (TNF) 
Chapt er 1 
The discovery of tumor necrosis factor (TNF) (reviews see: ' 
Ruff and Gifford 1981, Old 1985,1988, Beutler and Cerami 1988) 
properly began with the work of William B. Coley, a surgeon at 
Memorial Hospital in New York from 1892-1931. He observed that 
spontaneous regressions of certain tumors in cancer patients 
were frequently accompanied by concurrent bacterial infections. 
In 1893, Coley used killed bacteria, and the mixture of 
Streptococcus pyogenes and Serratia marcescens to treat cancer 
and this mixture was later known as Coley's toxins. However, 
Coley's toxins elicited many symptoms similar to those ' of 
bacterial infections, such as fever and chills. Tumors in some 
patients treated with Coley's toxins diminished or disappeared, 
but the results were inconsistent. Afterward, radiation therapy 
and chemotherapy essentially overcame Coley's approach. 
In 1943, Murray J.Sheai and his colleagues at the National 
Cancer Institute identified and purified the active component of 
the gram-negative bacteria that caused tumor regression. They 
found that it was a complex fat and sugar containing compound 
now called lipopolysaccharide (LPS). LPS is now also known as 
endotoxin, which is a constituent of the bacteria's outer wall 
and that it has . both beneficial and harmful effects to human. 
Clinical applications of Shear's findings were limited because 
LPS was considered too toxic in human. 
Glenn Algire (1952) of National Cancer Institute suggested 
that turnor hernorrhagic necrosis was secondary to LPS-induced 
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hypotension and collapse of turnor vasculature. In the e arly 
1960s, it became clear that the necrotizing reaction observed 
following the injection of LPS was due to a transferrable factor 
produced by the host (O'Malley et al 1962). This factor, later 
identified in the serum of Bacillus Calmette- Guerin pretreated, 
endotoxin-injected mice (Carswell et a1 1975) and shown to exert 
a direct cytotoxic effect on tumor cells, was termed ,"tumor 
necrosis factor" (TNF). TNF was found to be a product of LPS 
activated macrophages (Satomi et a1 1981, Zuckerman et a1 1989). 
It was purified by following its ability to cause lysis of mouse 
fibrosarcoma (L-929) cells. Far from being a selective 
tumoricidal drugs, TNF proved to have marked toxicities to the 
·host, mirroring those of LPS in many respects. Indeed, TNF is 
proved to be one of the central mediators of LPS action (Bauss, 
et a1 1987). 
Lymphocytes from sensitized animals were also found to 
have the ability to lyse allogeneic targets (Govaerts 1960, 
Rosenau and Moon 1961). This led to the suggestion that a 
factor produced by the activated lymphocytes would probably be 
the mediator of the cell killing. This factor was known as 
lymphotoxin which contributed to the anti-tumor factor in 
mitogen-stimulated lymphocytes (Rosenau 1968). In 1984, both 
. recombinant tumor necrosis factor and lymphotoxin can be 
obtained by expression of its complementary DNA in Escherichia 
coli (Pennica et a1 1984). Human tumor necrosis factor has 
about 30% homology in its amino acid sequence with lymphotoxin. 
Moreover, both of this two cytokines have similar biological 
properties. These similarities prompted some researcher to 
adopt the nomenclature TNF-a for TNF and TNF-~ for ,lymphotoxin. 
2 
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Later, Bruce Beutler, Anthony Cerami (1986) disc overed 
that whereas lipoprotein lipase activity in adipocytes became 
suppressed in endotoxin-sensitive (C3H/HeN) mice following LPS 
administration, endotoxin-resistant (C3H/HeJ) animals did not 
respond to LPS in this way. However, a factor in the serum of 
LPS-injected C3H/HeN mice acted to suppress lipoprotein lipase 
activity in endotoxin-resistant animals. This factor was termed 
cachectin, in view of its presumed involvement in the 
pathogenesis of cachexia (Butler and Cerami 1986, Beutler 1988). 
Amino acid sequencing of cachectin., and cloning of the cDNA for 
the genes encoding cachectin and TNF-a, confirmed that the two 
molecules are identical (Tracey et s1 1989). 
2. Production of tumor necrosis factor 
TNF is defined according to Ruff and Gifford (1981) as "a 
substance that is found in the serum of animals sensitized to 
BCG (or certain other immunopotentiators) and challenged later 
with endotoxin and that causes the necrosis of tUrnors when 
passively transferred to tumor-bearing animals". 
Nowadays, recombinant DNA technology were applied to 
produce a large amount TNF. The availability of pure 
recombinant TNF stimulates much more intensive investigations of 
this cytokine in recent years. 
TNF was produced by a two-step method in vivo. The first 
step is the priming step and the second step is the eliciting 
step. The mechanism of priming is incompletely understood; 
however, priming appears to increase the number of TNF-producing 
macrophages present at the time of endotoxin injection, and to 
increase the transcriptional and translational response of these 
cells. It is also possible that priming leads to the formation 
3 
Chapter 1 
of a ' larger 'stored' pool of TNF mRNA, which i s mobilized f o r 
immediate translation in the presence of endotoxin . Table 1.1 
shows different priming agents which have been used. 





Sheep red blood cells 
Mycobacterium lepraemurium 
Propionibacterium 
Zymosan (Saccharomyces cerevisi8e) 





OK432 (Streptococcus Pyogenes 
group A type 3) 
Muramyl dipeptide ' (HDP) 
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Although injection of priming agents is essential to 
produce TNF in vivo, it has been reported that TNF can be 
produced in monocytes in vitro without ' the application of the 
priming agents. For examples, Zuckerman et a1 (1989) reported 
that LPS could stimulate the murine macrophage to produce TNF. 
Kleinerman et 81 (1989) reported that lithium chloride (Liel) 
could activate the human monocytes to secrete TNF. A cytokine, 
P48, which was recently identified in the supernatant of the 
human null cell leukemia cell line Reh for the differentiation 
apd cytolytic activity in HL-60 cells, was also reported to 
induce TNF secretion by human monocytes (Beezhold et s1 1989). 
Granulocyte-macrophage colony-stimulating facto~ (GH-CSF) c a n 
stimulate the human peripheral blood mononuclear cells to 
produce IL-1a, IL-1~ and TNF- a (Sisson and Dinarello 1988). 
4 
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The second eliciting step for the production of TNF in 
vivo involved the use of a small amount of endotoxin (Carswell 
et sl 1975) in the primed animals. Lipopolysaccharide (LPS ) 
from E. coli is the commonest choice. Although blood monocytes 
and tissue macrophages appear to be the principal sources for 
TNF, recent studies suggest that many other cells are also 
capable of synthesizing qachectin. (Table 1.2) 
TABLE 1.2 CELLS FOR THE TNF PRODUCTION IN VITRO 
Cells for TNF production in vitro 
Blood monocytes 
Tissue macrophages 
Natural killer cells 
T lymphocytes 
Bone-marrow-derived mast cells 
Human transformed B-cell LuKII 
Murine spleen cells 
Microglial cells 
3. Physiochemical properties of TNF 
References 
Kleinerman et 81 1989 
Zuckerman et a1 1989 
Beutler and Cerami 1987 
Steffen et sI 1988 
Beutler and Cerami 1987 
Williamson et ak 1983 
Havell 1987 
Frei 1987 
From an analysis of the TNF cDNA sequence, it seems that 
human TNF is synthesized initially as part of a larger precursor 
(pre-TNF) with 233 amino acids. The mature TNF has 157 amino 
acids and the presequence of 76 residues is most probably 
involved in the secretion of TNF. Two of which are cysteines 
joined by a disulfide bond in the mature TNF. 
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Fig 1.1 Amino acid sequence of human tumor necrosis factor 
(Pennica etal 1984) 
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The molecular weight 
45,000. SDS-Polyacrylamine 
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estimated by gel filtration is 
gel electrophoresis (SDS-PAGE) 
indicated a molecular weight of 17,000. The pI as determined by 
isoelectric focusing was 6.0. The recombinant human TNF retains 
its activity over the pH range 6-10 for 24 h at 4·C but is 
inactivated rapidly at lower pH values. It retains biological 
activity at 60°C for 30 min. at pH 7.4 but is inactivated 
rapidly at higher temperatures (Shirai et al 1985). Human TNF 
is secreted as an unglycosylated polypeptide. Its active form 
is thought to be trimeric (Smith and Baglioni 1987). The human 
TNF receptor is believed to be a glycoprotein of molecular 
weight 75 K (Smith et al 1986). Nowadays, the structure of 
human TNF trimer can be determined at 2.9 A resolution by X-ray 
crystallography (Jones et si 1989) (Fig.1.2). 
c 
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Murine tumor necrosis factor (MuTNF) has been produced by 
the expression of cDNA from murine macrophage-like cell l i ne 
PU5-l.S mRNA in Escherichia coli (Pennica et a1 1985). The cDNA 
enoodes a mature MuTNF with 156 amino acids, leaving a long 
leader of 79 amino acids. MuTNF contains one potential N-
glycosylation site, located at asparagine-7 in MuTNF. The Hr-
TNF and mouse recombinant TNF are quite similar to each other 
and about 80 percent homology was found in their amino acids 
sequence (Pennica et a1 1985). 
4. Biological activities of TNF on various cells in the mammal 
The gene coded for TNF has been found on chromosome 6 in 
man (Spies et a1 1986) and chromosome 17 in mouse (Nedaspasov et 
, . 
s1 1986). The mechanism by which TNF production is controlled 
-is still a mystery. Quiescent macrophages do not secrete TNF, 
it is produced de novo in response to an activating stimulus but 
not exist in a stored form. LPS leads to accelerated TNF gene 
transcription and to a striking accumulation of TNF mRNA within 
the cell; ·it also permits efficient translation of the TNF mRNA 
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TNF is rapidly and efficiently ' exported from the 
macrophage by circulation, binding to a high-affinity plasma 
membrane receptor that is widely distributed on somatic tissue 
(Beutler 1986). TNF suppresses the transcription of certain 
genes (Torti et 81 1985) and ' augments the transcription of 
others (Collins et a11986). Therefore, TNF alters certain 
metabolic and structural features of the target cells. For 
example, when TNF is mediating its cachexic effect, a variety of 
mRNA molecules specifically expressed by differentiated cells 
(including those encoding lipoprotein lipase, glycerolphosphate 
dehydrogenase, "the fatty acid-binding protein, acetyl CoA 
carboxylase, fatty acid synthetase, and the serine protease 
. adipsin) are suppressed in adipocytes, and chronic exposure to 
TNF leads to loss of cell lipid (Cornelius et a1 1988, Torti et 
s1 1985). In endothelial cells, altered patterns of antigenic 
expression may be observed following contact with TNF (Collins 
et s1 1986), together with a variety of morphologic changes 
(Clark et a1 1988), modulation of the role of the eqdothelium in 
coagulation (Nawroth and Stern 1986). in neutrophils, TNF leads 
to degranulation, increased phagocytic activity (Klebanoff , et a1 
1986), antimicrobial activity (Djeu et s1 1986), endothelial 
adhesion (Gamble et s1 1985) and activation of the respiratory 
burst (Klebanoff et s1 1986). TNF was recently discovered to 
inhibit the effect of thyroid-stimulating hormone (TSH) on the 
thyroid gland (Ozawa et s1 1988). TNF also mediates 
hypoalbuminemia in animals (Henning et s1 1988). 
TNF has been found to be an important immunomodulator . 
. 
TNF can activate natural killer (NK) cells and stimulate 
monocytes/macrophages in an autocrine fashion (Mannel et 81 
1 1 
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1989). TNF is also an endogenous pyrogen for the induction of 
the production of interleukin 1 (Dinarello et s1 1986) a nd 
granulocyte-macrophage colony-stimulating factor (GM-CSF) from T 
cell (Munker et a1 1986). 
TNF acts as an inflammatory mediator, both by a direct 
effect on th~ hypothalamus and by IL-1 induction (Dinarello et 
s1 1986). Moreover, it enhances chemotaxis of macrophages and 
neutrophils, increases their phagocytic and cytotoxic activity 
(Djeu et a1 1988). Moreover, TNF induces the production of 
prostaglandins and thromboxanes (Kettelhut et al 1987). In the 
recent years, elevated ;TNF could be found in specific human 
disease states. Much of this discovery has been attributed to 
the development of specific enzyme-linked immunoabsorbant assay 
(ELISA). Waage et si (1987) claimed that high titre _of TNF was 
detected in samples from 10 of 11 . meningococcal meningitis 
patients who died but only lower titre of TNF was found from 8 
of 68 survived patients. Elevated concentrations of TNF have 
been noted in the serum of cerebral malaria patients (Grau et sl 
1989) and multiple sclerosis patients with inflammatory or 
autoimmune disease (Franciotta et al 1989). TNF could also be 
found in cancer patients with active disease (Balkwill et a1 
1987). TNF has been detected in serum samples obtained from 
HIV-seropositive (Lahdevirta et si 1988, Tracey and Cerami 1989) 
and alcoholic hepatitis (Mcclain and Cohen 1989) individuals. 
5. Mechanisms of anti-turnor action of TNF 
Tumor necrosis factor is a tumor necrotizing and cytotoxic 
factor. It has been reported that TNF causes necrosis of 
certain turnors in vivo (Carswell 1975) , and induces cytotoxic and 
cytostatic effects of certain turnors in vitro (Watanabe et al 
12 
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1985, Haranaka and Satomi 1981). After the recombinant TNF had 
been cloned, more and more about the biological activities and 
anti~tumor activities of TNF has been discovered. However, the 
mechanisms that mediates TNF-mediated cytotoxicity is still no t 
completely known nowadays. 
The screening of normal and tumor cell lines for their 
responses to TNF led to the ' general conclusion that TNF 
stimulate the growth of most nontransformed cells, while tumor 
cell lines are either unaffected or growth inhibited by 
incubation with this monokine. Table 1.3 summarizes many of the 
relevant data on this aspect (Shepard and Lewis 1988). The 
resistant turnor cell lines maintain TNF receptors of 
approximately the same number and affinity as sensitive turnor 
cells (Tsujimoto et s1 1985). TNF 'has previously been shown to 
be biologically active in heter~logous species both in vivo and 
in vitro (Old 1985). However, in recent studies, a preference 
\ 
for the homologous species does exist both in vitro and in vivo 
for TNF in human and murine system (Fransen et s1 1986, Kramer 
et a1 1988). 
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TABLE 1.3 THE RESPONSE OF DIFFERENT CELL LINES TO THE ACTION OF 
TNF-a OR TNF-fJ IN VITRO (SHEPARD AND LEWIS 1988) 
Growth enhancement 
CCD-18Co (normal human colon) 
Detroit 551 (normal human fetal skin) 
FS-4 (normal human foreskin) 
FS-48 (normal human foreskin) 
LL24 (normal human lung) 
NRK-49F (normal rat kidney) 
Osteoclasts 
WI-38 (normal human fetal lung) 
WI-IOO3 (normal human lung) 
Nun response 
A549 (human lung carcinoma) 
816 (murine melanoma) 
B 16Fl 0 (murine melanoma) 
CaJu-3 (human lung carcinoma) 
CMT-93 (murine rectal carcinoma) 
0-361 (human melanoma) 
HeLa (human cervical carcinoma) 
HeLa 098 (human cervical carcinoma) 
HT-29 (human cervical carcinoma) 
HT-I080 (human fibrosarcoma) 
KB (human oral epidermoid carcinoma) 
LS174T (human colon carcinoma) 
RD (human rhabdosarcoma) 
Saos-2 (human osteogenic sarcoma) 
SK-CO-I (human colon carcinoma) 
SK-LU-I (human lung carcinoma) 
SK-OV-3 (human ovarian carcinoma) 
SK-UT-l (human uterine carcinoma) 
S49 (murine lymphoma) 
T24 (human bladder carcinoma) 
WI-38 VA13 (human transformed WI-J8) 
14 
AntiprollIerattve ~~ 
BT-20 (human brea~t carcinoma) 
BT -475 (human breast carcinoma) 
B6M52 (murine sarcoma) 
B6M55 (murine sarcoma) 
CMS4 (murine sarcoma) 
CMS 16 (murine sarcoma) 
L929 (murine fibroblast) 
Men (human breast carcinoma) 
ME-180 (human cervical carcinoma) 
Meth A (murine sarcoma) 
MMT (murine breast carcinoma) 
SAC (Moloney-transform("d murine 3D) I 
SK-MEL-109 (human melanoma) 
SK-OV-4 (human ovarian carcinoma) 
UV 1591-RE (murine fibrosarcoma) 
WEHI-I64 (murine sarcoma) 
WiDr (human coh?n carcinoma) 
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.Measurement of the distribution of TNF after a single 
injection demonstrated that 31% of an administrated dose was 
entrapped in the liver, whereas the skin, gastrointestinal tract 
and kidneys contained another 30%, 8.8% and 7.8%, respectively 
(Spriggs et al 1987). After TNF bind to the receptor on the 
tumor cell surface, TNF molecule was found to be internalized 
into the cells (Frederick and Pedro 1981) via clathrin-coated 
through the classical receptor-mediated endocytosis pathway in 
L929 cells (Mosselmans et 81 1988) and then extensively degraded 
in the cell (Ohsawa and Natori 1988). The capacity of TNF to 
bind on and penetrate through cellular membranes is pH-dependent 
in human U937 cells (Baldwin et al 1988). Heat shock of WEHI-
164 fibrosarcoma cells significantly (and transiently) decreased 
the sensitivity of these cells to recombinant TNF-med~ated lysis 
(Gromkowski et al 1989). Aggarwal et 81 (1986) discovered that 
concanavalin A (Con A) caused an increase in TNF receptors 
without significant changes in their affinity constant but 
blocks the transduction of the signal for the cytotoxic response 
on human cervical carcinoma cell line ME180. 
The immediate effect of TNF added to cultures of L cells 
is cytostasis, manifested as cell arrest in G2 (Darzynkiewuz et 
s1 1984). A series of direct observations on the primary 
effects of TNF have been reported, for example, free hydroxyl 
radicals generation (Yamauchi et a1·1989) to produce oxidative 
damage to the DNA (Zimmerman et 81 1989). The reactive oxygen 
species (ROS) strongly correlate with the TNF cytotoxicity 
against L cell (Haranaka 1988). Another mechanisms are the 
release and activation of lysosomal enzyme (Sakurai et si 1985, 
Haranaka 1988) and protease (Kirstein and Baglioni 1986), 
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induction of the damage of the liposome membrane (Yoshimura and 
Sones 1987). Fragmentation of cellular . DNA is a nonspecific 
indicator of responsiveness to TNF (Berish et si 1988,1989). 
TNF mediated cytotoxicity involves ADP-ribosylation was observed 
in L929 (Agarwal et si 1988). Treatment with inhibitors of RNA 
synthesis potentiated the cytotoxic activity of Hr-TNF in L929. 
Hence, inhibition of mRNA synthesis was apparently responsible 
for the enhanced sensitivity to Hr-TNF (Kirstein et si 1986). 
Many studies indicated that actinomycin D and cycloheximide 
could enhance the Hr-TNF cytotoxicity on many turnor cells. It 
might be due to the blockade of actinomycin and cycloheximide on 
, the endogenous protective mechanism of turnor cells towards TNF 
(Creasey et a1 1987). 
The signal transductions ' after TNF binds to the receptor 
of tumor cell have recently be studied. Hasegawa and Bonavida 
demonstrated that the mechanism of TNF-mediated tumor cell lysis 
. does not depend on intracellular or extracellular Ca2 + and that 
events associated with target cell (human histiocytic 
U937) lysis· can also function in the absence of Ca2 + 
lymphoma, 
(Hasegawa 
and Bonavida 1989). The interaction of TNF with membrane 
receptors can increase GTP binding and pertussis toxin-sensitive 
GTPase activity in HL60 promyelocytic leukemic cells and L929 
cells (Imamura et si 1988). Exposure of TNF to human FS-4 
fibroblasts causes a rapid accumulation of intracellular cAMP 
and an increase in protein kinase activity (Zhang et si 1988). 
TNF was able ( to rapidly (within 30 min.) modulate tyrosine 
protein kinase activity of epidermal growth factor (EGF) 
receptors on HE-180 (Cervical carcinoma), which were sensitive 
to the cytotoxic effect of TNF but not alter EGF receptor kinase 
16 
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~t ivity ln TNF- resistant T24 (bladder c a rcinoma ) ( Donat o e t 81 
1989). 
TNF may directly. enhance its antitumor effect Vla 
incompleteli characterized vascular actions in v~vo (Fig.1.5). 
Mice bearing methylcholanthrene-induced A (Meth A) cells showed 
tumorivascular hemorrhage at 1-2 h after TNF administration, 
congestion at 4-6 h, and hemorrhage, congestion and blood 
circulation blockage at 24 h (Watanabe et 81 1988b). TNF 
impaired microcirculation by producing fibrin-like substances 
thrombus 1n newly formed microcapillaries which leaded to 
autolysis of the turnor cells (Shirnomura et 81 1988). 
l------1)NF apPlicro~I---------'l 
~------------~ ~----------~ 
Blood ,pressure 1 Tumour cell death Co~g.ulation i activity Endothelial lesions 
t ~ t / 
I Haemocon~r~;:~i~~:1 r 17 of thrombi I 
[Reduction of tumour blood flow I 
Fig. 1.5 Relevant pathophysiological mechanisms involved in 
reduction of turnor blood flow after TNF treatment (Kallinowski 
et 81 1989). 
TNF has been found to be an important immunornodulator. In 
I 
I 
the previous studies, TNF , has been demonstrated to activate 
rnacrophages both in vitro and in vivo ,(Mace et 81 1988) and 
increase a mixed lymphocytes response and act as an adjuvant for 
both T- and B- cells in vivo. Frederick et 81 (1989) claimed 
that neutrophils and rnonocytes available for participation in 
anti-turnor activity of TNF in vivo. Moreover, TNF demonstrated 
a potent dose-dependent effect on bone marrow stem cell number 
(Talmadge et 81 1988). In addition, TNF can activate natural 
killer (NK) cells (Mannel et 81 1989). Moreover, TNF can induce 
17 
t h e production of interleukin-1 (IL- 1) (Dinarello 
.' Chapt er 1 
et 81 1986 , 
Ghiara et 81 1987). IL-1 has been shown to regul ate several 
immunologic functions which are shared by TNF (Le and Vi lcek 
1987). In conclusion, the antitumor effects of TN F may be 
related to direct cytotoxicity, imrnunomodulatory effects o r 
endothelial effects on turn~r vasculature (Fig.1.6). 
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Fig.1.6 Predictive mechanism for the antitumor activity and side 
effects of TNF (Haranaka 1988) 
18 
-' .: Chapter 1 
Some tumors are resistant to TNF cytotoxic action. ~om e 
human tumor produce TNF in vitro and this 1S ass6ciated with 
resistance to the lytic effects of TNF (Spriggs et 81 1987). 
The induction of the synthesis of TNF in human and mur1ne cell 
lines by exogenous Hr-TNF indicates an inverse correlation with 
the sensitivity to the cytotoxic action of TNF (NUtsu et a1 
1988). Other pathways leading to resistance to TNF-a induced 
tumor cell cytotoxicity include the production of transforming 
growth factors by tumors cells and the amplified expression of 
certain oncogenes (Shepard and Lewis 1988). 
6. Clinical Studies of Hr-TNF 
TNF induces haemorrhagic necrosis of certain murine tumors 
(Carswell et 81 1975) and induces cytostatic and cytotoxic 
effects' in vitro (Watanab~ et 81 1985). These findings have 
I 
suggested "that TNF might be hseful for the treatment of human 
I 
I 
malignancies. The recent cloning and expression of the human 
TNF gen~ have made available sufficient quantities of this 
cytokine for the studies of its effects in humans. Phase I 
(Spriggs et 81 1987) and early phase 11 clinical trials (Lenk et 
81 1989) of Hr-TNF have been carried out in Japan, USA, UK and 
Germany (Spriggs et al 1987). 
There are several advantages of using Hr-TNF for the 
treatment of cancer patients. Firstly, TNF is selective to 
turnor cells and much less toxic to normal cells (Shepard and 
Lewis 1988). Secondly, TNF has little species specificity 
(Kramer et 81 1988). Thirdly, sufficient amounts of Hr-TNF-a 
are now available. Finally, combined treatment of ~-interferon 
(~-IFN) and TNF had a synergistic effect on tumor cytotoxicity 
(Williamson et 81 19,83). 
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The phase I clinical trials evaluated seve ral important 
points about the application for the treatment of cancer 
patients. The routes of application of Hr-TNF includes 
intravenous injection (i.v.) (Feinberg et s1 1988), 
intramuscular injectio-n (i.m.)(Jakubowski et 41 1989), 
subcutaneous injection (s.c.) (Chapman et a1 1987), intratumoral 
injection (i.t.) "(Bartsch et s1 1989). Experimental and 
clinical studies indicate that TNF is relative high effective 
when administrated intralesionally (Bartsch et a1 1989). The 
direct antitumor effects 
prolonged infusions (Frei 
tolerated dose determined 
of TNF may also be maximized by more 
and Spriggs 1989). The maximum 
by Kimura et a1 (1986) was 1.6xl06 
units/m2 • The recommended phase 11 dose ' of Hr-TNF administrated 
as a five-day continuous infusion is 2.4xl05 u/m2 /day . (Sherman 
et s1 1988). The plasma half-life of single-bolus doses in 
human is 31 min.- 42 min. (Spriggs et a1 1987). 
In phase I clinical trials, few patients treated had 
objective beneficial responses. One of the clinical results was 
shown in table 1.4. 
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TABLE 1.4 CLINICAL RESULTS OF INTRALESIONAL APPLICATION OF TNF 
FOR THE TREATMENT OF ADVANCED CANCER PATIENTS (BARTSCH et 81 
1989) 
Pa/itn! ,haraclau(ia 
r.Ti'.'F-alpha Applic:uionsl Tot~ll\o. of 
-"" 
No. Age Sex Diagnosis Pretreatment dose wed:. applic3tiom Response Present st;uus 
1 31 f :'.1c1anoma S, BT 25 1 5 Ne Alive 
2 62 m Adenoo., lung S 50 2 10 :ViR Died of disease 
3 16 m Chondrosarcoma S, CHT 50 2 8 PO Alive 
4- -') :>- r Adcnoca., colon S, CHT 50 3 22 PD Alive 
5- 56 f Breast a. S, CHT, HT, RT 75 3 6 PO Died of dise;ue 
6 54 r Liposarcoma S, CHT 75 3 10 PO Died of disease 
7 57 f :v1c1anoma S, CHT 100 1 + PO Alive 
8 59 m Squamous ccll S, CHT, RT 100 1 5 PR Died of disease 
ca., oropharynx 
9 63 r ~1 uc~pidcrmoid ca. S 100 2 9 :-;C Alive 
10 61 m SSLC S, CHT, RT 100 3 10 :-;C Died of disease 
G 47 r Bre:ut ca. S, CHT, HT, RT \ 150 2 19 PO Died of disea.se 54 m Histiocytoma S, CHT, RT 150 3 32 PR Alive 
13 37 m )"lclanoma S, CHT 200 2 40 PR Alive 
14 67 m OstC'Osarcoma .S 300 3 24 :'1R Alive 
S = surgery; BT = biological therapy; HT = hormone therapy; RT ::1 radiotherapy"; CHT = chemot.herapy. 
MR:minor response; NC~no change; PD:progressive diseas~; 
CR:complete response; PR:partial response 




The reasons of few responses of cancer patients t o Hr-TNF 
treatment may be due to the following reasons (1) The opt imal 
mode of administration of Hr-TNF was undiscovered. ' (2) The Hr-
TNF therapy had many side-effects such that the clinical the rapy 
of cancer patients may be discontinued. (3) Combined treatments 
of Hr-TNF with other therapy have seldom been applied. (4) The 
advanced cancer patients were usually heavily pre-treated such 
that the tumor may be very resistant to any further treatments. 
(5) Some tumors are resistant to Hr-TNF anti-tumor effect. 
Rapid development of resistance to TNF anti-tumor action may 
also occur (Shepard and Lewis 1988). 
Many systemic toxicities were 'reported after the 
application of Hr-TNF in patients. These includes fever, 
chills~ ' fatigues, rigors, anorexia, nausea with vomiting, 
headache, hypertension and hypotension. Other toxicities have 
included liver function abnormalities, transient neurological 
changes and haematological abnormalities (Spriggs et a1 1987). 
In phase 11 clinical trials, the maximum tolerated dose of 
Hr-TNF through i.v. or i.t. injection and the optimal dose 
level, schedule, and duration of treatment must be clarified. 
If direct cytotoxic effects are to be evaluated, TNF should be 
administered over periods of 12 hours or more. Heavily 
pretreated and advanced cancer patients should be excluded from 
~these initial studies to determine efficacy. The combination of 
Hr-TNF with other cytokines such as gamma-IFN and IL-2, 
immunptoxins, hyperthermia, chemotherapeutic agents and 




AIM OF INVESTIGATION 
Tumor necrosis factor (TNF) is a serum factor in 
endotoxin-treated mice which has been previously infected with 
Mycobacterium bovis strain BCG (Carswell et s1 1975) or othe r 
immunopotentiators. It has been reported that TNF causes 
necrosis of certain turnors in vivo (North and Havell 1988) and 
induces cytostatic or cytotoxic effects in vitro (Watanabe et sl 
1985, Haranaka and Satomi 1981) of Bome tumors. Anti-turnor 
therapy by the induction of endogenous TNF by OK-432 in human 
was also reported {Mikio et s1 1985). 
The induction of TNF in vivo involves the application of 
priming agents and eliciting agent. For priming agents, zymosan 
~ 
(Saccharomyces cerevisiae) (Haranaka et a1 1984b) is one of the 
best candidate because it is less toxic than other bacteria. 
Lipopolysaccharide (LPS), also known as endotoxin is known to be 
the most ' commonly used eliciting agent (Old 1985). Therefore, 
zymosan and LPS are used in our project to induce TNF in vivo 
for the treatment of Ehrlich ascites turnor (EAT) bearing mice. 
In order to get the most effective treatment of EAT 
bearing mice, the routes and dosages of administration of 
zymosan and LPS will be investigated. However, LPS have a wide 
range of pathophysiological effects in both human and 
. experimental animals. The toxic effects of LPS includes the 
mediation of cachexia, fever and inflammation (David and Syed 
1982). LPS was found t6 inhibit the lipoprotein lipase (LPL) 
and · induce the hypertriglyceridemia (Masanobu and Anthony '1981). 
LPS was found to directly mediate the insulin-like and 
hypoglycemic action (Linda and James 1983). LPS also increase 




a ntagonizing factor and a variety of vasoactive mediato rs ( David 
and Syed 1982). The toxic effects of LPS limit its use f o r the 
treatment of cancer in vivo. However, previous studies (Fung e t 
81 1988, Ha et 81 1987, Kettelhut et 81 1987) showed that 
certain "non-steroidal anti-inflammatory drugs (NSAID) or insulin 
suppression drugs such as mannoheptulose can partially protect 
bacteria-primed mice against endotoxin shock without affecting 
the ability of animals to release TNF. Therefore, NSAID such as 
sulindac and mannoheptulose will be applied to protect the 
zymosan -primed and LPS-elicited mice from endotoxin shock. The 
other side-effects of LPS such as change in glucose level in 
serum and ascitic fluid, body weight as well as body temperature 
will also be studied. 
TNF is induced in EAT bearing mice in our model. The 
relationship between EAT cell burden and the amount of TNF being 
found in serum or ascitic fluid as well as the therapeutic 
effectiveness will be studied. Previous studies of using Hr-TNF 
in combination with hyperthermia, chemotherapy, or immunotherapy 
can obtain good antitumor effect without side effects (Haranaka 
et 81 1987). In order to increase the anti-tumor and 
therapeutic performance of in vivo production of TNF for the 
treatment of EAT bearing mice, the combined treatments of in 
vivo production of TNF with methotrexate (MTX), 
polyriboinosinic-polyribocytidylic acid (poly 1°C), N-
(phosphonacetyl)-L-aspartate (PALA), hyperthermia will also be 
investigated. 
Although intensive investigations about the anti-tumor 
effect of TNF have been carried out in recent years, the actual 
mechanisms of the action of TNF on tumor cell were still not 
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c ompletely known. However, many previous studies indicated that 
the depletion of nucleotides and the consequent inhibit i on of 
DNA, RNA and ·protein synthesis (Fung et 81 1988) might have 
constituted the primary chain of events leading to the EAT cell 
death. Therefore, the effect of in vivo production of TNF on 
DNA, RNA and protein synthesis in EAT cells will be investigated 
in this studies. In the previous studies, TNF containing serum 
(Fung et 81 1985), methotrexate (Chan et 81 1983), N-
(phosphonacetyl)-L-aspartate (Leung et 81 1984), interferon 
inducer (Fung et 81 1986) and hyperthermia (Fung et 81 1988) 
have been reported to inhibit the glucose uptake of EAT by , 
decreasing· the number of glucose carriers on the tumor cell 
surface. Hence, the effect of in vivo production of TNF on 
glucose uptake in EAT will be examined. 
TNF was shown to be identical to cachectin whlch can 
mediate cachexia (Beutler and Cerami 1986). The weight loss and 
anorexia of cachexia are accompanied by accelerated muscle 
proteolysis and adipose-tissue lipolysis, and by increased 
hepatic rates of fatty acid oxidation and gluconeogenesis from 
lactate, amino acids and glycerol (Starnes et 81 1988). Hr-TNF 
can cause a dose and time-dependent suppression of the activity 
of lipoprotein lipase in the fully differentiated 3T3-L1 
adi~ocytes (Price et 81 1986). Therefore, Hr-TNF and LPS are 
used to investigate their effects on lipolysis in isolated rat 
adipocytes. The results can be used to determine if Hr-TNF and 
LPS acts in a non-time dependent manner analogous to catabolic 
hormones (epinephrine). Moreover, the side-effects of in vivo 
production of TNF on the lipolysis, body weight and body 




MATERIALS AND METHODS 
A. MATERIALS 
1. Animals 
Mouse: Female ICR mice, 30-35g, were bred in the University 
I 
i 
Animal House, the Chinese University of Hong Kong. 
Rat: Male Sprague-Dawley rats, 150-190g, were also 
supplied by the University Animal House. 
2. Cell lines 
In vi tro: L929, a murine fibrosarcoma, was kept in the 
laboratory by continuous culture and 
cryopreservation. 
Ehrlich ascites tumor (EAT) cells, an ascites 
derivative of a spontaneous murine mammary 
adenocarcinoma (tetraploid subline Ny Klein 
Strain) , were kept ln the laboratory by 
continuous culture and cryopreservation. 
In vivo: EAT cells were kept by serial intraperitoneal 
(i.p.) passage weekly in ICR female mice. 
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3 . Ra d i ochemicals 
All radiochemicals listed below we r e supplied by Amer s h a m 






2-Deoxy-D-[1-3H]-glucose,17 Ci/m mole 
L_[U- 14 C]-Leucine, 342 mCi/m mol 
[Methyl-3H]-Thymidine, 87 Ci/m mol 
[5-3H]-Uridine, 28.4 Ci/m mol 
4. Chemicals 
All chemicals listed below were of analytical grade 
unless otherwise stated. 
Chemicals 
Ascorbic acid 
BSA (Albumin, Bovine, Fraction V) 
Calcium chloride (CaClz .2HzO) 




disulfonic acid disodium salt 





Sigma (U.S.A. ) 
Merck (Germany) 
Sigma (U.S.A. ) 
Sigma (U.S.A. ) 
Sigma (U.S.A. ) 
S igma (U . S . A. ) 
Fisher (U.S.A.) 





Fetal calf serum (FCS) 





ethanesulfonic acid (HEPES) 
Human recombinant TN~ (Hr-TNF) 
Lipopolysaccharide (LPS) from 
Escherichia Coli 0127:B8 









Potassium chloride (KCl) 
Potassium dihydrogen phosphate (KHzP04) 




Sigma (U . S .A . ) 
Merck (Germany) 




Si gma (U. S . A. ) 
Merck (Germany) 




Si gma (U. S . A. ) 









Si gma (U. S . A. ) 
Chemicals 
Sodium chloride (NaCl) 
Sodium bicarbonate (NaHC03) 
Sodium dodecyl sulfate (SDS) 
Sodium metabisulfite (NazSzOs) 
Sodium periodate (NaI04) 
Sulfuric acid (HZS04) 
Sulindac 
Toluene 



















Rohm & Haas 
Sigma (U.S.A.) 
Gibco (Scotland) 
Si gma (U. S . A. ) 
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B. METHODS 
1. Preparation of Reagents 
Culture Medium 
RPMI 1640 medium (Sigma, with 25 mM HEPES) was used. The 
powder medium was dissolved in double distilled water and 
buffered with 25 mM NaHC03 according to manufacturer's 
specification. Sterilization was attained by means of 
filtration through a 0.22 urn millipore membrane filter. The 
plain medium was stored at 4·C. During cell culture, the plain 
m~dium was supplemented with 50 units/ml penicillin, 100 ug/ml 
streptomycin, 0.3% (w/v) glucose, 0.03% (w/v) " L-glutamine, and 
5% (v/v) fetal calf serum (FCS) (for L929 cells) or 10X (v/v) 
FCS (for EAT cells). For in vitro assay of TNF cytotoxicity, 
heat inactivated FCS (heated at 56·C for 30 min.) was used. The 
supplemented RPMI medium was defined as complete RPMI medium and 
was "ready for cell culture. 
Kreb-Ringer Buffer (KRB) 
KRB was prepared by dissolving 1.00g CaC12, 1.00g HgS04, 
1.00g KH2P04, 1.00g KCI, 10.00g NaCI, 0.273g NaHC03 in 100 ml 
distilled water. After mixing, 
02-5%C02 at least for 10 min., 
1 N NaOH. 
the solution is gassed with 95X 
then adjusted the pH to 7.4 with 
Kreb-Ringer Buffer with bovine serum albumin (KRB-BSA) 
KRB-BSA was prepared by dissolving 4g BSA to every 100 ml 
KRB-buffer. The final pH was adjusted to 7.4. 
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Neutral red 
0.5g of neutral red (BDH) was mixed with 100 ml normal 
saline. Insoluble dye was removed by filtration through Whatman 
No.l filter paper. 
Normal saline 
Normal saline was prepared by dissolving 9.00g NaCI in 1 
litre distilled water. 
Phosphate Buffered Saline (PBS> 
PBS was prepared by dissolving a.OOg NaCl, 0.20g KCl, 
0.20g KHzPO. and 1.15g NazHP04 in one litre distilled water. 
The pH was adjusted to 7.4 before used. Half-PBS was prepared 
by 2 folds dilution of PBS with distilled water. 
Scintillation Fluid 
Triton X-toluene scintillant was prepared by mixing 12.0g 
PPO, 1.2g POPOP, 2.0 litre toluene and 1.0 litre triton X-lOO. 
The suspension was stirred overnight until all the PPO and POPOP 
was dissolved. 
2. Cell Culture 
L929 in vitro 
lXl06 cells were seeded in a Corning 75 cm2 tissue culture 
flask containing complete RPM! medium (with 5% FCS) and 
incubated in a humidified atmosphere at 37·C (NUAIRE,NU-2500,C02 
incubator) with 5%COz and 95% air. The cells were cultured for 
3 to 4 days until spindle shaped cells were grown to a 
monolayer. They were then harvested by means of 2-minute 
Chapter 3 
trypsinization by 1 ml trypsin (0.25% trypsin plus 0.0 2X EDTA 1n 
sterilized normal saline). The cell suspension was was hed once 
with RPM! medium and re suspended in complete RPM! medium. 
EAT in vitro 
2X105 cells were seeded in a Corning 75 cm2 tissue culture 
flask containing complete RPM! medium (with 10% FCS) and 
incubated in a humidified atmosphere at 37°C (NUAIRE,NU-2500, 
C02 incubator) with 5% C02 and 95% air. EAT cells in culture 
were passed every 4 days by 10 fold dilution with fresh complete 
RPM! 1640 medium. 
EAT in vivo 
The EAT cells was maintained by weekly passage ~n ICR 
female mice. 107 cells in 0.2 ml PBS were injected i.p. into the 
mice and after 7 days the tumour bearing mice were killed by 
cervical dislocation. The EAT containing ascitic fluid was then 
collected and the cells were washed once with half PBS. The 
cells were resuspended in PBS and the cell number was adjusted 
to 5xl07 cells/ml in order to perform another passage. 
3. Lymphocytes proliferation 
The methods of Li et al (1987) was followed with slight 
modification. The mouse was killed by cervical dislocation. 
The killed mouse was placed on a clean surface with ventral side 
up and the anterior ':abdominal region was dampened with 70% 
alcohol. , The skin and membrane of the abdomen was cut and 
pulled apart. Spleens were removed and sliced into small pieces 
with scissors. A vertical motion was used to press the tissue 
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chunks with the syringe plunger onto the stainless steel mesh 
(14 strands mm-I). The collected cells were wa8he~ twice with 
half-PBS to remove the erythrocytes. Then lymphocytes were 
adjusted to 1xl08 /ml by complete RPM! (10 % FCS). 10 ul 3 H-
, thymidine (1 mCi/ml) were added into 1 ml cells suspension. 
After incubation at 37·C in 5XC02, 95X air for 16 h. The cells 
were then harvested through GF/C filter paper by a cell 
harvester. The filters were subsequently washed with 5X TeA and 
absolute ethanol. Filters were dried in oven at 60·C and placed 
in scintillation vials c~ntaining 4 ml triton X-toluene 
scintillant. The radioactivities were measqred with a Beckman 
LS-1801 liquid scintillation counter. Background absorption of 
radioactivity was corrected by addition of radioactive 
precursors after incubation and immediately before the harvest 
o,f cells. The unit was expressed as cpm/106 lymphocytes. 
4. In vitro production of Tumor Necrosis Factor (TNF) by 
peritoneal macrophages of ICR mice 
The method of Zuckerman et s1 (1989) was followed with 
slight modification. The mouse was killed by cervical 
dislocation. The killed mouse was placed on a clean surface 
with ventral side up and the anterior abdominal region was 
dampened with 70X alcohol. The skin of the abdomen was cut and 
pulled apart. Seven ml of ice cold RPMI were injected i.p •. 
. . Peritoneal fluid was collected by using a 10 ml syringe fitted 
with a 21-gauge needle. The peritoneal cavity of mice were 
washed two times. The cells were pelleted at 250 x g for 5 min. 
and washed with cold PBS twice before suspended with 10X FCS 




and incubated at 37·C and 5 % C02 for 3 h to allow the 
macrophages to adhere. The culture flask was then washed by PBS 
and the macrophages were collected by trypsinization. The 
macrophages were ~djusted to 8xl05 /ml. One ml of macrophages 
were added into each well of 24 well plates(Nunc). The 
macrophages were incubated at 37·C and 5XC02 for 16 h. The 
supernatant was then aspirated and replaced by the drugs 
(Zymosan or LPS). After 4 h. incubation in 37·C and 5% C02, the 
supernatants were collected and used for TNF titre assay. 
5. Production of TNF in animals 
Production of TNF in mice 
, Zymosan was dissolved in PBS by ~onication. , Mice were 
injected intraperitoneally. with 2 mg - 11 mg zymosan i~ 0.5 ml 
PBS and challenged intravenously with 25 ug LPS from E.Coli six 
days after zymosan injection. Two h after LPS was injected, the 
mice were bled from their subclavin vessels to obtain serum. 
TheTNF-containing serum (TNS) was filter-sterilized, heated at 
56·C for 30 min. and stored at -20·C until use. 
Production of TNF in rats 
Rats were injected intraperitoneally with 30 mg zymosan 
in 3 ml PBS and challenged intravenously with 125 ug LPS from 
E.coli 6 days after zymosan injection. The ,rat was bled at 
the tail 2 h after LPS injection. The TNF-containing serum was 
filtered-sterilized, heated at 56·C for 30 min. and stored at -t 
20·C until use. 
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6. Determination of TNF titre 
L929 was used as the target cells to assay TNF 
cytotoxicity. L929 with 4XI04 cells per well were seeded in a 
96-well tissue · culture plate (Nunc) in 100 ul complete medium 
and incubated at 37·C for 18 h. The medium was then aspirated 
and replaced with TNF containing sample at serially diluted 
doses. One ug of cycloheximide was added to each well to 
increase the assay sensitivity. After further incubation for 24 
h, the relative number of viable cells in each well was 
determined by neutral red uptake method. At the end of drug 
assay, medium of the microtiter plate was aspirated. The plate 
was then rinsed with PBS, 50 ulof neutral red (0.5% in normal 
saline) was added into each well and incubated at 37·C for an 
hour. Neutral red was then aspirated and the plate was rinsed 
with two times of PBS. The whole plate was dried in an oven at 
SO·C. 100 ul SDS (1%) was added to dissolve the intracellular 
dye. The amount of dye uptake was measured by an ELISA reader 
(Titertek Uniskan, Flow Laboratory) at wavelength 540 nm • 
. The percentage target cell inhibition (T.l.) of cells at 
each dilution of sample was calculated by the following formula: 
T.I.=[100 x (N-E)/N]% where N = O.D.S40 of control sample and E= 
O.D.S40 of sample with TNF cytotoxicity. T.I.so is defined as 
the concentration of sample (v/v) in culture medium such that 
T.I. of this culture is 50%. The TNF titre is defined as the 
reciprocal of the concentration of sample at T.I.50. 
7. ' Determination of TNF containing serum titre on EAT in vitro 
Viable EAT cells with 6xl05 in 0.5 ml complete RPM! medium 
(with - 5% HIFCS) were added to each well of a 24 well (Nunc) 
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plastic tissue culture plate. Half ml of complete medium with 
different dilutions of serum sample was added. .Then four ul 
cycloheximide (250 ug/ml) was added to each well. The plates 
were incubated at 37·C for 24 h. The viable cell count after 
the incubation was determined after the addition of 0.5 ml 0.3% 
trypan blue to each well. 
8. Mortality determination of mice 
Mice were observed at different time interval after the 
treatmernt. The percentage of survival was calculated by the 
~ 
following formula: 
percentage of survival survived mice at different time 
at different time = -----------------------------~- x ' 100% 
Total mice 
9. 3B-thymidine. 3H-uridine, 14C-leucine incorporation 
The method of Fung et sl (1988b) was followed with minor 
modifications. For measuring thymidine, uridine and leucine 
incorporation, EAT cells taken from mice were washed and 
re suspended with fresh complete RPM! 1640 . (10% HIFCS) to lxl06 
·cells/ml. One hundred ul cell suspensions were added into test 
tubes and then mixed with 10 ul 3H-thymidine(50 uei/ml) or 3H-
uridine(50 uCi/ml) or 14C-Ieucine(5 uCi/ml). After incubation 
at 37·C for 3 h, 6 h, 6 h in 3H-thymidine, 3H-uridine, 14C-
leucine incorporation measurements respectively, the reaction 
was stopped by addition of 1 ml cold 5 % trichloroacetic acid 
(TCA). \ The cells were sonicated for 10 seconds. The cells were 
then harvested with ice cold 5% TCA through GF/C filter by a 
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cell harvester. The filters were subsequently washed with 5% 
TeA and 10 ml ice 'cold absolute ethanol. Filters were dri ed in 
oven and placed in scintillation vials containing 4 ml triton x-
toluene scintillant. The radioactivities were measured with a 
Beckman LS-1801 liquid scintillation counter. Background 
absorption of radioactivity was corrected ' by addition of 
radioactive precursors after incubation and immediately before 
the harvest of cells. 
10. Glucose uptake determination 
The method of Fung et s1 (1988b) was followed with minor 
modifications. For studying 2-Deoxy-D-[3H]-glucose uptake, EAT 
suspension (2x10 7 /ml in PBS) were equilibrated to 37°C. At zero 
second, 0.2 ml cell suspension was mixed with 0.2 ml. pre-warmed 
2-Deoxy-D-[3H]-glucose. Reaction was stopped after 6 sec. by 
transferring 0.2 ml of mixture to 1 ml ice-cold PBS supplemented 
with 40 mM 2-Deoxy-D-glucose. Cells, were collected by 
centrifugation at · 15000xg for 10 sec. in an Eppendorff 5414 
microcentrifuge. The supernatant was removed and the cells were 
washed with 1 ml of the same buffer. Cell lysis was accomplished 
by. the addition of 0.2 ml 0.1% triton X-100~ Triton X-toluene 
scintillant with 1.25 ml was added and the radioactivity was 
counted in a Beckman LS-1801 liquid scintillant counter. Non-
specific diffusion was corrected by subtracting the uptake in 
the presence of 10uH cytochalasin B (final concentration). 
11.Whole body hyperthermic treatment of EAT bearing mice 
Before the actual hyperthermic treatment was performed, 
the normal mice were firstly screened by placing them in a 
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constant temperature warm room of 43·C for 1 h. The survived 
mice after this heat treatment were considered to be physicall y 
strong enough for the following hyperthermic treatment. These 
screened mice were subjected to EAT inoculation. During 
hyperthermic treatment, EAT bearing mice were put into the 
constant temperature room of 43·C. After about 30 min., the 
body temperature ' of mouse increased to 41·C. 
treatment was last for 45 min. at 41·C body 
The hyperthermic 
temperature. The 
body temperature of mouse at anus was monitored by a electronic 
thermocouple , (Y8I. Tele-thermometer). 
12.Lipolysis assay 
The method of Butcher et a1 (1~68) was followed with minor 
modification. Crude epididymal fat tissues were obtained from 
male rats (150g-190g) and immersed 'in Krebs Ringer Buffer and 
then washed twice to remove debris. Washed fat tissues were 
blotted on filter paper, weighed and cut in KRB-BSA solution 
into about 2mm strips. Tissues were put into a plastic 50 ml or 
10 ml capped centrifuge-tubes. For every gram of fat tissue, 
1.5 mg of collagenase and 2 ml KRB-BSA solution were ' ,added. 
Ninety-five % 02 five % C02 were then gassed on top of the 
tube. The mixture in the tube was incubated at 37·C for 2 ' h. 
Digested tissues were filtered through cheesecloth and washed 
with KRB-BSA solution. Purified adipocyte suspension were added 
into microfuge tubes containing drugs solution. The mixture of 
the tube was, incubated at 37·C with 95 % 02 -5 % C02 for a 
period of time. After incubation, equal volume (500 ul) of 10% 
TeA was added to stop reaction. Tubes were centrifuged at 
10,000 x g or more for 20 min •• Two hundred ul supernatant was 
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removed from tubes for glycerol determination. 
Lipolysis was determined by measuring the amount o f 
glycerol released in our experiment. Fo~ glycerol 
determination, 50 ul of 1 N HZS04 was added followed by 50 ul of 
50 mM sodium periodate (NaI04) to the Bupernatant. After 5 min., 
50 ul of 10% sodium metabisulfite (Na2S20s) was added. After 5 
min., 2 ml chromotropic acid reagent was added 0 The tube 
contents were mixed and boiled for 30 min •• Absorbance at 
570nm(ODs7o) were read. Under vacuum filtration, aliquots of 
fat cells were collected on Whatman GF/B glass fibers in 
triplicate. They were dried in an incubator at 60·C for at 
least 24 h. The average weight of filter was subtracted from 
the weight of dried filters with adipocytes to give the dry 
weight of adipocytes. The rate of lipolysis is expressed by mM 
glycerol/g cell/hour. 
13.Statistical analysis 
All results are expressed as 
standard deviation (S.D.). Student's 
the arithmetic mean and 
t-test is used to 
determine the confidence limits in experiment comparison. 




IN VIVO PRODUCTION OF TUMOR NECROSIS FACTOR 
USING ZYMOSAN AND LIPOPOLYSACCHARIDE 
INTRODUCTION 
Zymosan A is a yeast cell wall polysaccharide. It is 
composed of essentially intact yeast cell walls and hydroglucan 
of much smaller fragments of irregular size and shape. Zymosan 
was originally tested against Sarcoma 180 (S-180) in mice for 
its possible turner inhibitory properties (William et 81 1958). 
I 
i 
The studies with zymosan in mice bearing 8-180 indicate that 
under certain conditions ~ this material is capable of promoting 
tumor regression by the host defense reaction. Zymosan (Z) was 
found to activate the properdin sys~em and combine - with the 
properdin (X) to yield a complex (ZX) (Anne et 81 1974, Volker 
et 81 1973). Properdin 1S a relatively heat-labile, normal 
serum protein that, in the presence of complement component q3, 
acts nonspecifically against gram-negative bacteria and viruses 
and plays a role in lysis of erythrocytes. The complex (ZX) 
comprises two multi-unit enzymes capable of cleaving complement 
components C3 and C5, respectively. Therefor, zymosan can · 
activate the alternative pathway of the complement system. 
Moreover, the zymosan can activate the reticuloendothelial 
system and increase the production of phagocytic cells in 
splenic tissue (Irene et 81 1962, Yukiko and Goro 1972). 
Therefore, a host mediated phenomenon was responsible for 
regression oftumors by zymosan-treated mice. However, the 
mechanism of the action of the zymosan is not the same as that 
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of lipopolysaccharide (LPS) isolated from bacteria and tumor 
necrosis factor (TNF) because zymosan do not cause hemorrhage 
~ithin the tumor. 
TNF was firstly discovered by Carswell and her colleague 
in 1976 (Carswell et sI 1975) in the serum of mice infected with 
Bacillus Camette-Guerin (BCG) and challenged subsequently with 
LPS. However, it was recently discovered that zymosan can 
substitute BCG as the priming agent in the production of TNF 
(Haranaka et s1 1984b). In our project, zymosan is used to act 
as the priming agent to produce TNF in vivo. Ehrlich ascites 
turnor (EAT) bearing mice were used as animal mode. The ICR 
strain mouse was chosen as our animal model because it can be 
supplied in a large amount 
activity while comparing 
and it can produce higher TNF 
with other nude mice (Haranaka et sl 
1984a). The origin of EAT is a solid line of Ehrlich carcinoma, 
an epithelial mammary carcinoma of mouse. It was first 
converted into ascitic form by Lowenthal in 1932 and afterwards 
this tumor model was widely used in cancer research (Yoshida 
1971). The subline of EAT used in our laboratory is Ny Klein 
which was converted from solid Ehrlich carcinoma by Klein and 
Klein ' (1956) into the ascitic form and used as the tetraploid 
Ehrlich ascites turnor. Since this tumor cell line is easy to 
handle and maintain either in vivo or in vitro and it is 
sensitive to TNF cytotoxicity (Ha et s1 1985a), it ' is a good 
model for assessing the effect of TNF on turn~r growth. 
In this chapter, the effect of zymosan and LPS on the 
immune system will be studied. Moreover, the appropriate amount 
and routes of the application of zymosan and LPS, the time of 
LPS injection after zymosan priming to produce TNF to kill EAT 
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Female ICR strain mice, about 30-35g body weight , were 
used. Zymosan A and lipopolysaccharide (E.coli serotype 
0127:B8) were products of Sigma. Zymosan was dissolved in PBS 
(pH 7.4) by sonication. LPS was also dissolved in PBS (pH 7.4). 
Lymphocytes proliferation 
Groups of 4 mice were injected with 0.5 ml PBS containing 
2 mg zymosan i.p. or 0.2 ml PBS containing 25 ug LPS i.v .. 
Group of 4 untreated mice were used as the control. In one 
experiment (results shown in Fig.4.1), four days after zymosan 
injection, spleen of each mice was dissected. In another 
experiment (results shown in Fig.4.2), six days after zymosan 
injection, LPS was injected and one day after LPS injection, 
spleen of each mouse was dissected. The lymphocytes 
proliferations were ' investigated as described in chapter three 
"materials and methods". 
In vitro production of TNF by peritoneal macrophages 
The.macrophages were removed from the peritoneal cavity of 
the normal mice as described in chapter three "materials and 
methods". After the m~crophages were incubated at 37°C and 5% 
C02 for 16 h in a 24-well plate, the supernatant was then 
aspirated and replaced by 1 ml RPMI with 5% heat inactivated 
fetal calf serum (HIFCS) containing 0.5 mg zymosan or 1 ug LPS. 
After 4 h incubation in 37°C and 5%C02, the supernatant were 
collected and used for TNF titre assay. 
In vivo production of TNF to kill EAT cell in mice 
.; . 
On day 0, 2x105 EAT in 0.2 ml PBS was inoculated i.p. into 
each mouse; One day later, 2 mg-11 mg zymosan was injected i.p. 
to each mouse. Several days after zymosan injection, 6.25-25 ug 
43 
LPS was injected i.v. 
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to each mouse. Mice were bl ed from t heir 
subclavian vessels after LPS injection. Pool e d sera were 
filter-sterilized, heated at 56°C for 30 min. and sto red frozen 
at -20·C until use for the determination of TNS titre. Two days 
after the LPS injection, EAT cells of groups of at least 7 mi c e 
were collected by exhaustive drainage and harvested by 
centrifugation. Pooled cells were washed once with half-PBS to 
remove the erythrocytes. The final cell suspension was prepared 





Table 4.1 shows that both zymosan and LPS could increase 
the weight of spleen and induce splenomegaly in normal mice. 
The zymosan and LPS were shown to possess the ability to 
activate the proliferation of lymphocytes in spleen of normal 
mice in Fig.4.1. Single dose of zymosan can activate the 
lymphocyte proliferation by about 150 % - 200 X of the control 
(Fig.4.1 a, b). Single dose of LPS or zymosan combined with LPS 
can activate the proliferation up to 250 % (Fig.4.1 b). 
The effect of the zymosan only or LPS only on the 
stimulation of the peritoneal macrophages to release TNF in 
vitro or in vivo were also studied. Fig.4.2 showed that the TNF 
titre assay of the supernatant of macrophage suspension after 
stimulation by zymosan or LPS~ The TNF titre was determined 
according to chapter three "materials and methods". The results 
of Table 4.2 indicated that 0.5 mg zymosan or 1 ug LPS could 
induce TNF release by peritoneal macrophages in vitro. 
Therefore, zymosan and LPS play an important · role on the immune 
system. 
Table 4.3 indicated that no TNF could be found in serum of 
EAT bearing mice. Therefore, the serum of EAT bear~ng mice can 
be used as the control for the determination of TNS titre when 
zymosan and LPS are injected to these mice. 
The effect ·of in vivo production of TNF on EAT cells 
growth was studied. Growth of EAT cells were suppressed 
slightly in vivo after the single injection of zymosan or LPS 
(Table 4.4). However, zymosan (Fig.4.3) or LPS (Fig.4.4) only 
could not prolong the life of the EAT bearing mice. 
Table 4.5 shows that a significant amount of TNF can be 
45 
Chapter 4 
induced by LPS in zymosan ' primed mice as less as 6 days a fter 
zymosan injection. 
Fig.4.5 showed that the TNF production in sera of normal 
zymosan-primed mice was the highest 2 h after LPS injection. ' 
Therefore, 2 h after LPS injection was chosen to bleed the mice 
for the determination of TNF titre in serum (TNS) in the 
following ,experiments. Fig.4.6 also showed that the TNF titre 
in ascitic fluid was also the highest 2 h after LPS injection. 
Fig.4.7 showed that the TNF containing serum obtained from , 
EAT-bearing mice could also exert EAT cytotoxicity in vitro 
other than L929 cells. In Fig.4.5, the titre of TNF measured by 
L929 assay was 12,000 whereas by EAT assay was 10,000. 
Table 4.6 and 4.7 showed that increasing the amount of 
, 
zymosan followed by injection of 6.25 ug or 25 ug of LPS can 
enhance the production of TNF in EAT bearing mice. As little as 
2 mg zymosan followed by LPS injection can produce TNF in serum 
in both tumor-bearing or normal mice. From Table 4.8, it was 
found that in zymosan-primed or normal EAT bearing mice, the 
higher the LPS dosage, the higher theTNF being induced in vivo. 
As little as 6.25 ug LPS could produce a maximal amount of TNF 
in serum of z~mosan primed normal mice. By comparing the 
results in Table 4.6, Table 4.7 and Table 4.8, EAT bearing mice 
produced lower amount of TNF titre in serum at the corresponding 
doses of zymosan or LPS respectively than in normal mice. 
{ Table 4.9 shows that the EAT cell number can influence the 
amount of TNF in serum in EAT bearing mice. The higher the EAT 
cell (number in mice, the lower the TNF being found in serum of 
mice. TNF titre in serum was very little in groups of 1xl06 and 
lxl07 EAT inoculation mice. 
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Table 4.10 showed that the in vivo production of TNF 1cQuld 
inhibit the proliferation of EAT. LPS only can produce a little 
amount of TNF, the suppression of the proliferation by such a 
little amount of TNF is lower than that of the combined 
treatment of zymosan and LPS which produce a large amount of 
TNF. On the other hand, zymosan only was incapable of producing 
TNF six days after its injection, as well as suppressing the 
proliferation of EAT. 
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TABLE 4.1 EFFECT OF ZYMOSAN AND LPS ON THE RATIO OF SPLEEN 






Spleen wt./Body wt. 
(mg/g) 
3.814 ± 0.627 
9.691 ± 2.213* 
6.889 ± 0.444** 
8.387 ± 1.032** 
On day 0, 5 mg zymosan was injected i.p. into groups of three 
normal mice. On day 6, 25 ug LPS was injected i.v .. On day 7, 
spleens of each group were removed from the peritoneal cavity 
and the ratios of spleen wt. to body wt. were determined. The 
data are expressed as mean ± S.D. of 3 measurements. The 
difference between the group of control and treatments are 
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Fig.4.1 The effect of zymosan and LPS on lymphocytes 
proliferation of ICR mice. (a) On day 0, 2 mg zymosan were 
injected i.p. into groups of four mice~ On day 4, spleens were 
removed from the peritoneal cavity and the lymphocytes 
proliferations were determined. (b) On day 0, 2 mg zymosan were 
injected i.p .. On day 6, 25 ug LPS was injected i.v. On day 7, 
spleens were taken out from different groups and the lymphocytes 
proliferations were determined according to chapter three 
"materials and methods". Groups of four untreated normal mice 




Table 4.2 IN VITRO PRODUCTION OF TNF BY PERITONEAL MACROPHAGES 
a Treatment 
0.5 mg zymosan 
1 ug LPS 
bTNF titre 
140 ± 15 
85 ± 35 
Peritoneal macrophages were incubated with 0.5 mg zymosan or 1 
ug LPS in 1 ml RPM! with 5% HIFCS for 4 h. The supernatant were 
taken out and used for TNF titre assay. Complete medium (RPMI 
with 5% HIFCS) .~ was used as control. Data are expressed as mean 
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Fig.4.2 TNF titre assay using L929 cell line. Peritoneal 
macrophages were incubated with 0.5 mg zymosan p,6)or 1 ug LPS 
~,~in 1 mlRPMI with 5% HIFCS for 4 h. The supernatant were 
taken out and used for TNF titre assay. Complete medium (RPMI 
with 5% HIFCS) was used as control. The method of TNF titre 
determination was described in the legend in Chapter three 
"materials . and methods". 
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Table 4.3 TNF TITRE IN SERUM OF EAT BEARING MICE 
a Treatment 
EAT cell number 
for inoculation 
2x10 5 (7 days) 
1x10 7 (7 days) 
1x10 7 (10 days) 
Chap ter 4 
bTNS titre 
o ± 0 
o ± 0 
o ± 0 
a Different 
bled 7 days 
determined 
from normal 
mean ± S.D. 
amounts' of EAT were inoculated on day o. bMice were 
or 10 days after EAT inoculation, TNS titre was 
from pooled sera of four mice of each group. Serum 
mice was used as control. Data are expressed as 
of four determinations. 
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Table 4.4 IN VIVO PRODUCTION OF TNF BY ZYMOSAN OR LPS ONLY TO 
SUPPRESS EAT GROWTH 
a Treatment 
EAT 
EAT,5 mg zymosan 
EAT,25 ug LPS 
Tumor number 
% of control 
100 ± 23.4 
65.3 ± 20.0* 
76.4 ± 13.4** 
bTNS titre 
o 
56 ± 10 
50 ± 30 
aGroups of 10 mice were inoculated 4x104 and 2x10 5 EAT for 
zymosan -treated group and LPS treated group respectively on day 
O. For zymosan treated group, 5 mg zymosan was injected i.p. on 
day 6 and EAT cell number of 7 mice were counted one day after 
the zymosan injection. For LPS treated group, 25 ug LPS was 
injected i.v. on day 7 and EAT cell numbers of 7 mice were 
counted on day 9. bThe mice were bled 2 h after injection of 
zymosan or LPS, TNS titre was determined from pooled sera. EAT 
bearing mice serum was used as control. Data are expressed as 
mean ± S.D. for 3 determination. The differences between 
treatment group and each of the control group are determined by 
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Fig.4.3 ' Effect of zymosan only on survival of EAT bearing, mice. 
On day 0, 4xl04 EAT were inoculated into groups of 20 mice. On 
day 6, 5 mg zymosan was injected into each mouse. The % of 
survival of EAT bearing , mice were monitored on the indicated 
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Fig.4.4 Effect of LPS only on survival of EAT bearing mice. On 
day 0, 2xl05 EAT were inoculated into groups of 20 mice. On day 
7, 25 ug LPS was injected i.v. into each mouse. The % of 
survival of EAT bearing mice were monitored on the indicated 
days. (~)EAT control; (A) LPSj (O)EAT, LPS. 
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TABLE 4.5 EFFECT OF DAYS AFTER PRIMING BY ZYMOSAN ON TNF 








200 ± 20 
17800'± 50 
17800 ± 35 
17800 ± 30 
aEach mouse was injected with 5 mg zymosan on day O. On the 
indicated days, 25 ug LPS was injected. bMice were bled 2 h 
after LPS injection, TNS titre was determined from pooled sera 
of five mice of each group. Normal mice serum was used as 
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Fig.4.5 Time course of TNS titre in zymosan-primed mice after 
the injection of LPS. On day 0, 5 mg zymosan was injected i.p .. 
On day 6, 25 ug LPS was injected i.v .. At the indicated times 
after LPS injection, mice were bled. TNF titre in serum was 
determined from pooled sera from 3 mice in each group. Data are 
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Fig.4.6 Time course of TNF titre in ascitic fluid of zymosan-
primed EAT bearing mice after the injection of LPS. On day 0, 
2x10 5 EAT were inoculated i.p.. On day 1, 5 mg zymosan was 
injected i.p .. On day 7, 25 ug LPS was injected i.v .. At the 
indicated times after LPS injection, the ascitic fluid from the 
peritoneal cavity was collected using centrifugation to remove 
the EAT cells. The TNF titre in the ascitic fluid was 
determined according to the "Materials and Methods" in Chapter 
3. Control ascitic fluid was taken from EAT bearing mice. Data 
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Fig.4.J , The cytotoxic effect of TNF contai~ing serum on EAT in 
vitro. On day 0, 2x10 5 EAT was inoculated i.p. into the mouse. 
On day 1, 5 mg zymosan was injected i.p .. On day 7, 25 ug LPS 
was injected i.v .. Mouse was bled 2 h after LPS injection. 
Serum containing TNF titre with 12,000 by L929 assay was used 
for the determination. The method was described in Chapter 
three "materials and methods". 
~- . 
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TABLE 4.6 EFFECT OF THE AMOUNT OF ZYMOSAN ON THE IN VIVO 








2x10 5 EAT 0 
inoculation 
180 ± 20 794 
457 ± 30 1047 





a Each mouse was inoculated with 2x10 5 EAT on day 0, zymosan was 
injected i.p. one day later. On day 7, 6.25 ug LPS was injected 
i.v .. b Mice were bled 2 h after LPS injection, TNS titre was 
determined from pooled sera from 3 mice in each group. EAT 
bearing mice serum was used as control. Data are expressed as 
mean ± S.D. of 4 measurements. 
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TABLE 4.7 EFFECT OF THE AMOUNT OF ZYMOSAN ON THE IN VIVO 










100 ± 20 
500 ± 20 
1445 ± 50 
titre 
0 EAT 
420 ± 30 
1380 ± 40 
'2510 ± 50 
aEach mouse was inoculated with 2xl05 EAT on day 0, zymosan was 
injected i.p. one day later. On day 7, 25 ug LPS was injected 
i.v .. bMice w~re bled 2 h after LPS injection, TNS titre was 
determined from pooled sera of four mice in each group. EAT 
bearing mice serum was used as control. Data are expressed as 




TABLE 4.8 EFFECT OF DOSES OF LPS ON IN VIVO PRODUCTION OF 










2x10 5 EAT o EAT 
inoculation 
0 ± 0 0 ± 0 
14 ± 10 560 ± 50 
10 ± 14 500 ± 100 
2300 ± 35 17800 ± 50 
4400 ± 40 17200 ± 39 
6900 ± 30 17250 ± 90 
aOnday 0, 2x105 EAT were inoculated. On day 1, 5 mg zymosan 
was injected i.p .. On day 7, 1, 5, 6.25, 12.5 or 25 ug LPS was 
injected i.v .. bMice were bled 2 h after LPS injection, TNS 
titre was determined from pooled sera of four mice of each 
group. EAT bearing mice serum was used as control. Data are 
expressed as mean ± S.D. of four determinations. 
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Table 4.9 ' EFFECT OF EAT BURDEN ON THE IN VIVO PRODUCTION OF TNF 
USING ZYMOSAN AND LPS 
a Treatment 






aDifferent amounts of EAT were inoculated 
zymosan was injected one day after. On 
injected i.v .. bMice were bled 2 h after 
titre was determined from pooled sera 
group. EAT bearing mice serum was used as 
"expressed as mean of four determinations. 
63 
bTNS titre 
8000 + 50 
4200 ± 50 
60 ± 10 
60 ± 10 
on day o. 7.5 
day 7, 25 ug LPS 
LPS injection, 








~-able 4.10[: EFFECT OF IN VIVO PRODUCTION OF TNF ON THE 







% of control 
100.0 ± 7.4 
112.1 ± 22.0* 
76.4 ± 13.4* 
49.31 ± 23.62* 
CTNS titre 
o ± 0 
o ± 0 
40 ± 16 
3800 ± 300 
aEach mouse was inoculated with 2x10 5 EAT on day 0, 2 mg zymosan 
was injected into groups of 20 mice on day 1. On day 7, 25 ug 
LPS was injected i.v .. bEAT cells were counted on day 9 of 
groups of at least 7 mice. CMice were bled 2 h after LPS 
injection, TNS titre was determined from pooled sera from four 
mice of each group. EAT bearing mice serum was used as control. 
Data are expressed as mean ± S.D .. The differences between 
groups of control and treatments are determined by the Student's 
t-test. *P<0.002. 
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DISCUSSION 
In the immune system, after the lymphocytes (e.g. B-
lymphocytes and T-lymphocytes) are generated in the primary 
lymphoid organ, the lymphocytes will migrate into the secondary 
peripheral organ "lymphocyte traffic". Spleen is a well 
organized encapsulated lymphoid organ. The other one is the 
lymph nodes. The bulk of the lymphoid tissue in spleen is 
arranged around a central arteriole the periarteriolar 
lymphoid sheath (PALS). The PALS is composed of T and B cell 
areas, the T cells being found around the central arteriole 
while the B cells are found beyond this zone. The lymphocytes 
showed an increase of the proliferation after the application of 
zymosan and LPS (Table 4.1, Fig.4.1). It indicated that the 
zymosan . and lipopolysaccharide (LPS) can act as an 
immunopotentiator. The zymosan has been reported to activate 
the host-mediated , immunological reaction which involves the 
stimulation of the lymphocytes and macrophages in the liver, 
spleen and reticuloendothelial system (Irene 1962). LPS is a 
constituent of the outer cell wall of gram-negative bacteria 
(e.g. E.co1i). It plays an important effect on the immune 
system (e.g. complement system (Pangburn et s1 1980); 
immunoglobulins (Ginsberg and Horrison 1978); B lymphocytes 
(Lemke 1975, Andersson 1972); T lymphocytes (Schmidtke and 
Najarian 1975); macrophages (D'Onofrio and Paradisi 1983); 
polymorphonuclear leukocytes (eohn 1960); basophilic 
granulocytes (Horrison and Betz 1977». 
Two h after LPS injection was chosen to bleed the mice to 
get the serum for TNS titre determination. It is because the 
peak of TNS titre appeared 2 h after LPS injection (Flg.4.5). 
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In my studies, the TNF titre determination in serum and asc itic 
fluid was carried out using in vitro L929 cytotoxic ity. 
Although it is not a very specific and accurate method for t he 
determination of TNF titre, the basic rationale of the method is 
agreeable with the definition of TNF claimed by Ruff and Gifford 
(1981). Therefore, we strongly believed that the anti-tumor 
effect of serum from normal mice or EAT bearing mice as well as 
ascitic fluid was mainly due to the TNF appeared in the serum or 
ascitic fluid. 
My studies indicated that both zymosan and LPS can 
activate the peritoneal macrophages to release TNF in vitro 
(Fig.4.2, Table 4.2). Our results are agreeable to the results 
of studies of Zuckerman et sl (1989) and Satomi et s1 (1981). 
Both zymosan andLPS can also stimulate the mice to release TNF 
in vivo (Table 4.4). Moreover, the zymosan primed EAT bearing 
mice have been showed to produce at least 50 times more amount 
of TNF after the subsequent challenge ~ith LPS six days later 
while comparing with that of using either zymosan or LPS alone 
(Table 4.7). Previous studies by Flick and Gifford (1986) 
demonstrated.that the amounts of TNF of LPS injection in 
unprimed normal mice were approximately 200-fold less than those 
found in C.psrvum-primed mice. Therefore, like C. parvu_, 
zymosan · is also a good priming agent for the production of TNF 
in mice in vivo. Zymosan also has the advantage of being less 
toxic than other priming agent such as BCG (Carswell et s1 1975) 
or Listeria monocytogene (Ha et a1 1985a). Therefore, zymosan 
can offer a valuable potential for the clinical application for 
the in vivo production of TNF in patients in the future. 
From the results of the effect of different amounts of 
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zymosan on the production of TNF in EAT bearing mice o r no rmal 
mice, the higher the amount of zymosan produce higher titre o f 
TNF (Table 4.6, 4.7). As little as 2 mg zymosan elicited the 
appearance of TNF in serum in normal mice or EAT bearing mice 
after the injection of LPS. Two to five mg zymosan was chosen 
to the mice in our project. 
It was s~rprised that the TNS titre after LPS injection in 
zymosan-primed EAT bearing mice was lower than that of the non-
EAT bearing mice (Table 4.6,4.7,4.8). Moreover, the higher the 
number of EAT inoculated in mice, the smaller the amount of TNF 
being found in serum (Table 4.9). There are two possible 
explanation for this phenomenon. Firstly, some researchers 
reported that a ~arge amount of turnor products can suppress the 
host immune system (Michael and George 1981). Therefore, the 
EAT cells might suppress the TNF release in the serum. The 
other possible explanation is that the TNF being produced in the 
serum might pass into the peritoneal cavity (Fig.4.6) such that 
the TNS titre being detected in serum of EAT bearing mice was 
less than that of ·non-EAT·bearing mice. 
: Frances and Richard (1987) reported. that labile TNF-like 
activity. was detected by means of an enzyme-linked immunosorbent 
assay in serum from cancer patients with active disease. Other 
research group found that TNF is a humoral ~ediator of cachexia 
in the rat bearing methylcholanthrene-induced sarcoma (Hark et 
s1 1989). On the other hand, other group reported that TNF 
could not be found in cancer patients (Moldawer et s1 1988). In 
my investigation, no TNF titre was detected in serum of EAT 
bearing mice seven days and ten days after EAT inoculation in 
our model (Table 4.3). It is possible that the EAT bearing mice 
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cannot produce TNF spontaneously. However, the failu re to 
detect TNF uniformly in the disease states may be attributed t o 
the kinetics of TNF production. The inability to detect TNF in 
serum of EAT bearing mice may reflect 
-interval (Moldawer and Lowry 1988). 
an inadequate sampling 
An additional difficulty 
with emphasizing circulating concentrations is that local tissue 
production of TNF may be more important than . the systemic 
appearance. Nevertheless, because 
account for almost 90% of total 
fixed tissue macrophages 
body macrophages, the 
quantitative contribution these organ make to whole-body 
production is sizable. For example, Lonnroth et s1 (1988) 
reported that spleens ' and tumors of cachectic mice bearing a 
methylcholanthrene-induced sarcoma are spontaneously producing 
cachectin and interleukin 1, despite the fact that detectable 
levels are not observed in the serum. 
From my results, the in vivo production of TNF has been 
found to kill the EAT cells in mice (Table 4.4, Table 4.10)~ 
This is due to the TNF direct cytotoxic effect on EAT cell and 
the effect of host mediated immune system. Moreover, TNF 
containing serum from EAT bearing mice can also kill EAT in 
vitro (Fig.4.7). It is because EAT is one of the most 
susceptible cell line to the cytotoxic effect of TNF (Ha et a1 
1985a). LPS or zymosan only could also produce a little amount 
TNF and kill a little amount of EAT in vivo (Table 4.4). The 
result indicated that the TNF amount being induced was directly 
related to the efficiency of . the EAT killing effect. It is 
because the combined application of zymosan and LPS could 
produce a large amount of TNF and kill a large amount of EAT in 
vivo simultaneously. ' LPSonly was also reported for inducing 
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the TNF in human (Hamish 1988, David et s1 1988) and use d for 
turnor kiiling in animals (Micheal and Paul 1976, Hichael et s1 
1978, Hohamed et s1 1989). There are three possible mechanisms 
for the effects of endotoxins on host-turnor interactions: (1) a 
direct effect of endotoxins on the growth of turnor cells 
themselves; (2) the stimulation of host mediation systems to 
destroy the malignant cells by activation of non-specific host 
defense systems; and (3) endotoxins may stimulate the host 
immune system to reject immunologically the foreign cells and 
achieve a state of immunity against subsequent exposure to the 
tumor. However, the zymosan or LPS only could not prolong the 
life of the EAT bearing mice. It is expected that the combined 
application of zymosan and LPS possess the potential for the 
treatment of EAT bearing mice. In conclusion, th~ in vivo 
production of TNF by the combined use of zymosan and LPS can 
provide a method for clinical trial for the treatment of cancer 
in human. 
From the gathering of the results from the trials in the 
experiments, a protocol of in vivo production of TNF using 
zymosan and LPS for the treatment of EAT bearing mice could be 
finally derived. On day 0, EAT was inoculated i.p. into each 
mouse. On day 1, 2-5 mg zymosan was injected i.p. into each 
mouse. On day 7, 25 ug LPS was injected i.v. into each mouse. 
It was because after about at least 6 days (Table 4.5), a 
significant amount of TNF can be induced by the challenge of 
LPS. The dosage of 25 ug LPS was chosen since 25 ug LPS could 
induce higher TNF amount than that of 12.5 ug and 6.25 ug LPS in 
EAT bea~ing mice , (Table 4.8). Higher TNF production is expected 




SIDE-EFFECTS DURING IN VIVO PRODUCTION 
. OF TUMOR NECROSIS FACTOR IN EHRLICH ASCITES TUHOR BEARING MICE 
INTRODUCTION 
Bacterial lipopolysaccharides (LPS), also known as 
endotoxin, have a wide range of pathophysiological effects and 
some beneficial effects in both human and experimental animals 
(Review see Old (1988». One of these beneficial effects is the 
induction of the release of tumor necrosis factor (TNF) into 
sera of animals infected with bacteria, for examples 
Corynebacterium parvum (Ha et s1 1985a) or Listeria 
monocytogenes (Ha et s1 1985a). However, endotoxins are also 
. 
known to produce a plethora of potentially deleterious 
pharmacological effects including vascular hypotension with 
decreased peripheral resistance and a marked metabolic acidosis 
(David and Syed 1982). Levels of peripheral blood cells and 
plasma proteins are also altered significantly, often 
accompanied by deposition of fibrin in tissues. The other major 
toxicities of LPS include the mediation of cachexia, fever and 
inflammation. Cachexia is the gross imbalance of the host 
physiological state including the carbohydrate and lipid 
metabolism. Endotoxin was found to directly mediate the 
insulin-like and hypoglycemic action in rats (Linda arid James 
1983). Endotoxin was also found to inhibit the lipoprotein 
lipase (LPL) and induce thehypertriglyceridemia due to impaired 
removal of triglyceride from the circulation (Kawakami and 
Cerami 1981). Endotoxin injection was found to cause the fever 
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in human which 'was similar to the reaction of TNF (David et 81 
1988, Hsmish et s1 1988). There are considerable evidences from 
both in vitro and in vivo studies, including clinical studies o f 
patients with gram-negative bacteria, to suggest that endotoxins 
will . affect the host inflammatory cells, for examples, 
macrophages (D'Onofrio 1983) , polymorphonuclear leukocytes 
(Moeller et a1 ' 1978), mast cells (Roitt 1989). LPS can increase. 
the production and release of prostaglandins, ' a glucocorticoid 
antagonizing factor and a variety of vasoactive mediators (David 
and Syed 1982). 
Many results suggested that TNF could act as an endogenous 
mediators of endotoxin effects (Hamish et s1 1988, David et s1 
1988). These toxic effects of LPS limit its use in the 
treatment of cancer in vivo. However, previous studies (Fung et 
a1 1988a, Ha et a1 1987, Kettelhut et s1 1987) showed that 
certain non-steroidal anti-inflammatory drugs such 'as 
acetylsalicylic acid, phenylbutazone, indomethacin, and sulindac 
or insulin suppression drugs such as mannoheptulose (Choy et a1 
1987) can partially protect bacteria-primed mice against 
endotoxin shock without affecting the ability of mice to release 
TNF. In view of the therapeutic potential of TNF, it is of 
interest in studying whether the ' combined administration of 
mannoheptulose and anti-inflammatory drugs can completely 
protect the zymosan-primed normal or EAT bearing mice from 




Female ICR strain of mice, . about 35g body weight, were 
used in all experiments. Zymosan was dissolved in PBS b y 
sonication. Sulindac and D-mannoheptulose are products o f 
Sigma. Mannoheptulose was dissolved in PBS. Sulindac was 
dissolved in PBS by sonication. 
On day 0, 2x105 EAT per mouse were inoculated i.p .. On 
day 1, 5 mg zymosan was injected i.p .. On day 7, 2 h before 25 
ug LPS was injected, sulindac at 1 mg in 0.2 ml solution was 
administrated by oral intubation. One h before the LPS 
injection, mannoheptulose of 9 mg (250 mg/kg body wt.) in 0.2 ml 
PBS was injected subcutaneously. The mice were bled from 
subclavian vessels 2 h after LPS injection. The sera were 
pooled, heat inactivated at 56°C for i h, filter-sterilized and 
stored frozen at -20°C until use. Control sera were obtained 
from EAT bearing mice. 
Two days after LPS injection, EAT cells in groups of at 
least 7 mice were collected by exhaustive drainage and harvested 
by centrifugation. Pooled cell were washed once with half-PBS 
to remove the erythrocytes. The final cells suspension was 
prepared in PBS. Cells were counted with a hemocytometer using 
0.3% trypan blue. 
The glucose level in sera and ascitic fluid of peritoneal 
cavity was determined by glucose kit 510 purchased from Sigma. 
Mortality determinations of mice after the injection of 
LPS and the TNF titre in serum was determined according to 
chapter 3 "materials and methods". 
The body weights of mice with different treatments were 
measured on the indicated days by an electronic balance (Ohaus 
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G4 00D) • 
The body temperatures of zymosan-primed mice a ft e r LPS 





Protection of EAT-bearing mice from endotoxin shock during the 
production of TNF by sulindac and mannoheptulose 
Fig.5.1 shows that the combined treatments of sulindac and 
mannoheptulose exhibited the highest protection (70% survival) 
of zymosan-primed EAT bearing mice after 48 h post LPS 
injection. The group of mice receiving LPS without drugs has 
the lowest percentage of survival (17% survival) at 48 h after 
LPS injection. Therefore, the combined application of sulindac 
and mannoheptulose can protect the EAT bearing mice from acute 
endotoxin shock. 
Table 5.1 shows that the TNF in serum (TNS) titre in EAT 
bearing mice was not affected by the application of sulindac and 
mannoheptulose. However, it should be noted that the protection 
of zymosan-primed mice against endotoxin shock by the combined 
treatments of sulindac and mannoheptulose was not complete as 
reflected by the fact that about 30% of mice died under these 
treatment after 48 h of LPS injection (Fig.5.1). 
Table 5.2 shows that sulindac and mannoheptulose neither 
suppress the EAT cells growth nor produce anyTNF in serum of 
EAT bearing mice. The data also shows that in vivo production 
of TNF in zymosan-infected mice challenged by LPS with or 
without drugs treatment could significantly suppress the EAT 
proliferation and the titre of TNS was high. 
Fig.5.2 shows that the zymosan-primed EAT bearing mice 
died immediately after the LPS was injected and the mortality 
rate is greater than that of EAT bearing control mice. Although 
TNF being induced in zymosan-primed and LPS challenged EAT 
bearing mice can kill certain EAT cells in these mice two days 
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after LPS injection, in vivo production of TNF cannot pro l ong 
their life., In contrast, the side effects of LPS may enhance 
the mortality and these side effects cannot be reversed by 
sulindac and mannoheptulose treatment. 
Effect of in vivo production of TNF on glucose metabolism of EAT 
bearing mice 
Table 5.3 showed that the zymosan-primed EAT bearing mice 
showed hypoglycemia while comparing with the normal mice. 
Moreover, the glucose level in serum of zymosan-primed EAT 
bearing mice after the injection of LPS was lower than that of 
zymosan-primed EAT bearing mice without the injection of LPS. 
The glucose level in ascitic fluid in the peritoneal cavity of 
EAT bearing mice was about 36.2 mg/dl. However, the glucose 
level in ascitic fluid of zymosan-primed mice after the LPS 
injection was almost equal to zero. 
Effect of in vivo production of TNF on bodY temperature of 
normal mice 
Fig.5.3. is a typical experiment showing that TNF 
production in zymosan-primed mice challenged with LPS exhibited 
a hypothermic effect in normal mice. The body temperature of 
• 
mice dropped lower than 35·C about 2 h after the LPS injection. 
In Fig.5.4, it has been shown that sulindac and · mannoheptulose 
could . not eliminate the hypothermic effect of TNF in these 
normal mice. 
Effect of in vivo production of TNF on body weight of EAT 
bearing mice 
Fig 5.5 shows that EAT cells growth could increase the 
host body weight probably because of the increase in the amount 
of ascitic fluid and turnor cells. The EAT cell burden in the 
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mice could maximally increase the body weight by about 50X of 
the original body weight on the day when the mice die d. In 
Fig.5.6, it has been shown that the body weight of EAT bearing 
mice on day 9 had 30% increase while comparing with that on day 
O. However, the body weight of EAT bearing mice primed with 
zymosan and challenged with LPS for the production of TNF was 
similar to that on day O. The body weight of normal mice primed 
with zymosan and challenged with LPS for the production of TNF 
had about 10% decrease comparing with that on day O. Sulindac 
and mannoheptulose had little effect in alleviating the side-
effects of weight loss. Fig.5.7 shows that EAT bearing mice 
treated with zymosan only on day 7 did not exhibit any change in 
body weight comparing with those of EAT bearing mice without 
treatment. The LPS only did not have any significant effect on 
body weight of -normal mice. Treatments of zymosan only on 
normal mice and LPS only on EAT bearing mice could decrease the 
body weight of mice slightly. 
Effect of EAT cells burden in mice on the mortality of mice 
I 
after the injection of LPS 
Fig.5.a shows the effect of LPS injection on survival of 
mice inoculated with different amount of EAT cells. Fig.5.8 (a) 
shows that 25 ug LPS itself did not kill any normal mice. For 
mice - inoculated with 2x105 EAT cells on day 0, LPS treatment on 
day 7 caused about 10 % of mice died immediately after injection 
and more mice died 11 days after LPS injection and all mice died 
16 days after LPS injection. Whereas in EAT bearing group, mice 
began to die on 11 days after LPS injection and all died 15 days 
after LPS injection. However, Fig.5.8 (b) shows that when mice 
were inoculated with 1xl07 EAT cells on day 0, LPS treatment on 
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i njection of group of 1x107 EAT inoculation was very h ig h. In 
Fig.5.9 (a), it has been shown that mice with 1x10 7 EAT 
inoculation died immediately and rapidly after the LPS injection 
even after the treatment of sulindac and mannoheptulose . 
However, the rates of survival of mice with 1x106 and 4x104 EAT 
inoculation after LPS injection were similar and were higher 
than that of 1xl07 EAT inoculation group. Normal mice under 
these treatments did not die. In Fig.5.9 (b), the rate of 
survival of mice with lxl0 7 EAT inoculation after the injection 
of LPS was smaller than that of EAT control mice. However, all 
of this two groups mice died out about 14 days after LPS 
injection (i.e. 21 days after LPS injection). In Fig.5.9 (c), 
the rate of survival of mice with 4x104 EAT inoculation after 
the LPS injection was also smaller than that of EAT control 
group. All of this two groups died out about 18 days after LPS 
injection (i.e. 25 days after EAT inoculation). 
As shown in Fig.5.10 (a), if much small amount of tumor 
cells namely lxl04 EAT cells were used for inoculation, only 10% 
mice of the zymosan and LPS treated group died due to the 
endotoxin shock. Sulindac and mannoheptulose could completely 
protect the EAT bearing mice from endotoxin shock. Moreover, 
some · mice have been completely cured under these treatments. 
Zymosan only had not any positive effect on survival of the EAT 
bearing mice. Fig 5.10 (b) also showed that 60 % EAT bearing 
mice of 2x104 EAT were completely cured under TNF production 
with sulindac and mannoheptulose treatments. 
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Fig.5.! Effects of combined treatment of sulindac and' 
mannoheptulose on the -time course of mortality of zymosan-primed 
mice after LPS injection. Groups of 20 mice were inoculated 
with 2x10 5 EAT on day o. On day 1,5 mg zymosan was injected 
i.p .. On day 7, mice received 28 mg/kg body wt. sulindac (0) 
orally or 250 mg/kg body wt. mannoheptulose (e) subcutaneously 
or a combination of sulindac and mannoheptulose (~) before the 
challenge of 25 ug LPS as described in the Experimental. A 
group of mice - (~) received LPS only on day 7. The % of survival 
were ~onitored after LPS injection.for 48 h. 
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TABLE 5.1 EFFECT OF TREATMENT OF SULINDAC AND MANNOHEPTULO SE ON 
TNF IN SERUM (TNS) PRODUCTION IN EAT BEARING MICE 
aTreatment bTNS titre 
EAT,zym,LPS 3800 ± 300 
EAT,zym,sulindac,LPS 3500 ± 200 
EAT,zym,mannoheptulose,LPS 3500 ± 500 
EAT,zym,SM,LPS 3500 ± 700 
aEach mouse was inoculated with 2xl0 5 EAT i.p. on day'O. 5 mg 
zymosan was injected i.p. on day 1. On day 7, 25 ug LPS was 
injected i.v. into each mouse. Sulindac and mannoheptulose were 
administrated to the animals in dosage and schedules as 
described in the Experimeptal. bMice were bled 2 h after LPS 
injection. TNF titre in serum was determined from pooled sera 
of 5 surviving mice in each ~roup. 
Abbreviations: 
zyrn = zymosan 
SM = Sulindac and D-mannoheptulose treatment 
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TABLE 5.2 EFFECT OF IN VIVO PRODUCTION OF TNF ON THE SUPPRESSION 




and mannoheptulose only 
Zymosan and LPS 
Zymosan,sulindac, 











± 17. 5* 
+ 2 • 5* 
CTNS tit r e 
o 
o 
3800 ± 300 
3500 + 700 
aEach mouse of groups of 20 mice was inoculated with 2xl0 5 EAT 
on day 0, 5 mg zymosan was injected into each mouse on day 1 . 
On day 7, sulindac, mannoheptulose and 25 ug LPS were applied 
according to the experimental bEAT cells in each group were 
counted on day 9. cMice were bled 2 h after LPS injection, TNS 
titre was determined from pooled sera from four mice of each 
group. Data are expressed as mean ± S.D. of four 
determinations . The differences between the groups of 
treatments and control are determined by Student's t-test. 
*P<O.OOl. 
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Fig.5.2 Survival of EAT bearing mice after the in vivo 
production of TNF. Groups of 20 mice were inoculated 2xl05 EAT 
on day. o. On day 1, 5 mg zymosan was injected into each mouse 
i.p .. On day 7, mice were given sulindac and mannoheptulose 
according to protocol described in the text before the i.v. 
injection of 25 ug LPS. The % of survival were monitored at the 
indicated days. ( 0 )EAT control; (e)EAT+Zym+SM+LPS; (6) 
EAT+Zym+LPS. 
· -81 . 
Chl1pte r fj 
TABLE 5.3 EFFECT OF IN VIVO PRODUCTION OF TNF ON GLUCOSE LEVEL 
IN SERUM AND ASCITIC FLUID OF PERITONEAL CAVITY IN EAT BEARING 
MICE 
aTreatment 







121.02 ± 6.14 
64.49 ± 2.56 
50.36 + 2.56 
36.18 + 15.3 






aOn day 0, 2xl0 5 EAT were inoculated into each mouse. On day 1, 
5 mg zymosan was injected i.p. into each mouse. On day 7, 25 ug 
LPS was injected i.v. into each mouse. bSerum and ascitic fluid 
were obtained on day 7 at the indicated times after LPS 
injectiori. Glucose level in each sample was determined by 
Glucose Kit 510. Data are expressed as mean + S.D. of 3 
measurements. The differences between the groups of treatment 












>-0 36.0 0 
m 
35.0+-----T-----~----~~~~--~----~----~----~ 
o 30 60 90 120 150 180 210 
TIME AFTER LPS INJECTION (min.) 
Fig.5.3 Effect of in vivo production of "TNF on body temperature 
of normal mice. Each mouse were injected i.p. with 5 mg zymosan 
on day o. Six days later, each mouse was injected i.v. with 25 
ug LPS. The body temperature was monitored by an electronic 
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Fig.5.4 Effect of in vivo production of TNF on body temperature 
of sulindac and mannoheptulose pretreated mouse. On day 0, 5 mg 
zymosan was injected. On day 6, sulindac, mannoheptulose and 25 
ug LPS were applied according to the experimental. The body 
temperature was monitored by an electronic thermocouple (YSI 
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Fig.5.5 The change of body weight of EAT bearing mice during the 
growth of the EAT cells. Nine mice were inoculated with 2xl05 
cells on day o. The body weight were measured on the indicated 
days post-transplantation un~il all EAT bearirig mice died. 
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Fig.5.6 The body weight change after different treatments of 
mice. The body weight of groups of at least 5 mice were 
monitored on day 0 and day 9 after EAT inoculation. On day 0, 
2x10 5 EAT were inoculated i.p. into each mouse. On day 1, 5 mg 
zymosan was injected i.p .. On day 7, sulindac, mannoheptulose 
and LPS were applied to the EAT bearing mice according to the 
experimental. Bars are mean ± S.D. for five determinations. 
The differences between treatment and c~ntrol groups (day 0) are 



























Fig.5.7 The body weight change after different treatments of 
mice. The body weight of groups of at least 5 mice were 
monitored on day 0, day7 and day 9 after EAT inoculation. On 
day 0, 2xl0 5 EAT were inoculated i.p. into each mice. On day 1, 
5 mg zymosan was injected i.p.. On day 7, sulindac, 
mannoheptulose and LPS were applied to the EAT bearing mice 
according to the experimental. Bars are mean ± S.D. for five 
determinations. The difference is determined by Student's t-
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Fig.5.8(a) Effe~t.of LPS only on survival of EAT bearing .. mice. 
25 ug LPS was lnJected 7 days ~fter 2xl0 5 EAT inoculation. The 
% of survival of EAT bearing mice were monitored on the 
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Fig.5.8(b) Effect of LPSionly on survival of EAT bearing mice. 
25 ug LPS was injected 7 days after lxl0 7 EAT inoculation. The 
% of survival of EAT bearing mice were monitored on the 
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Fig.5.9(a,b,c) Effect of EAT cell burden in mice on the 
mortality of mice after the injection of LPS. On day 0, lx10 7 , 
1xl06, 4xl0 4 EAT cells were inoculated into groups of 10 mice. 
On day 1, 5 mg zymosan was injected. On day 7, sulindac and 
martnoheptulose were applied according to experimental before the 
injection of LPS. The mortality of mice were monitored on the 
indicated days. Fig.5.9 (a) (O)4x10 4 EAT,Zym,SM,LPS; (6)lx106 
EAT,Zyrn,SM,LPS; (D)lxl0 7 EAT,Zym,SM,LPS; (0)0 EAT;Zym,SM,LPS. 
Fig.5.9 (b) (O)lx10 7 EAT,Zym,SM,LPS; (6.)lx107 EAT control. Fig.! 
- 5.9 (c} (O)4xl0 4 EAT,Zym,SM,LPSj (6.)4xl04 EAT control. 
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Fig.5.10 (a) Survival test of mice beared with low amount of EAT 
after in vivo production of TNF. On day 0, 1x104 EAT were 
inoculated. On day 1, 2 mg zymosan was injected i.p .. On day 
7, sulindac and mannoheptulose, 25 ug LPS were applied. (O)lxl04 
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Fig.5.10 (b) Survival testlof mice beared with low amount of EAT 
after in vivo production of TNF.. On day 0, 2xl04 EAT were 
inoculated. On day 1, 2 mg zymosan ,was inj ected i. p. . On day 
7, sulindac and mannoheptulose, 25 ug LPS were applied. (~)2xl04 
EAT control; (e)2xl04 EAT,Zyrn,SM,LPS 
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DISCUSSION 
In the previous studies (Ha et 81 1987, Fung et a1 1988a, 
Choy et 81 '1987), certain non-steroidal anti-inflammatory drugs 
such as acetylsalicylic acid, phenylbutazone, indomethacin and 
sulindac or insulin suppression drugs such as · mannoheptulose 
have been shown to protect Listeria-infected or C.parvum-primed 
IDlce against endotoxin shock without affecting the production of 
TNF in mlce. Sulindac and mannoheptulose were applied In my 
studies to protect the EAT bearing mice from endotoxin shock. 
The sulfide metabolite of sulindac was known to be an inhibitor 
of cyclooxygenase, which converts arachidonic acid to 
prostaglandins under a variety of physiologic and inflammatory 
conditions (Fig.5.A, Shen 1979). The sulfide of sulindac has 
been found to be an effective scavenger of the destructive and 
inflammatory oxidant radicals, which are generated as by-
products from various hydroperoxy intermediates 
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Fig. 5- ~ A , . Inhibi1ion of the cyclooxygenase pathway and oxidant radicals genE!rated in the I 
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Mannoheptulose was found to process the abili t y to b lock 
the insulin secretion (Simon and Kraicer 1972). The result s in 
Fig.5.1 showed that the combined treatments, sulindac plus 
mannoheptulose can increase the protection in the zymosan-primed 
animals against the lethal effect of LPS while comparing with 
individual treatment but do not affect the ability of animals to 
produce TNF (Table 5.1). However, no complete protection can be 
observed. It may be due to other biologically toxic effect 
mediated by LPS (e.g. the induction of glucocorticoid 
antagonizing factor (GAF) , (Goodrum et 81 1978) and hypotensive 
I 
• I 
activity (Badgy and Spltzer,1980)). Therefore, the drugs that 
can be used to protect !the IDlce from hypotensive shock is 
valuable for the further study. The results in Table 5.1 shows 
that the sulindac and mannoheptulose can protect the mice 
against the lethal effect of LPS but not affect the ability of 
mice to produce TNF. The large dose of NSAID can induce the 
side-effects of gastric irritation or the bleeding tendency and 
large dose of mannoheptulose is also toxic. However, the 
optimal dose of drugs used in this procedure can protect the 
mice from endotoxin shock without inducing any undesirable side 
effects. Hence, the application of sulindac and rnannoheptulose 
can protect the mice but do not decrease the therapeutic effect 
of TNF treatment. Table 5.3 indicates that hypoglcemia occurred 
after the LPS injection in zymosan-primed EAT bearing mice. It 
is agreeable with the previous findings that the LPS (Linda and 
James 1983) and TNF (Evans et 81 1989) are responsible for the 
hypoglycemia in vivo. The hypoglycemia induced by LPS also 
mediate the decrease of glucose level in ascitic fluid in the 
peritoneal cavity. 
94 
As shown in Table 5.2 and Fig.5.2, 
that the in vivo production of TNF 
Ch8p ter 5 
it was so d isappo int e d 
can suppress the 
proliferation of EAT by 40% two days after LPS injection, but i t 
cannot prolong the life of EAT bearing mice while comparing with 
the control. Moreover, the mice died immediately and rapidly 
after the LPS challenge even the sulindac and mannoheptulose 
were applied and the rate of mortality is greater than that of 
the EAT bearing mice control. It may be due to the side-effect 
induced by LPS. Moreover, the recurrence of EAT in mice also 
induced the death of mice. Treatment with sulindac and 
mannoheptulose only possessed short term protection on mice. 
Therefore, the in vivo production of TNF only one time in this 
method could not prolong the life of the mice despite the 
sulindac and mannoheptulose were applied or not. Fig.5.8 (a) 
shows that the LPS inje6tion induced very high lethality in 
I ' 
I 
lxl0 7 EAT inoculation group. On the other hand, no EAT bearing 
mice died after LPS injection in 2xl0 5 EAT inoculation group 
(Fig.5.8(b)). ' As shown in Fig.5.9 (a,b,c), the larger the EAT 
burden in mice, the higher the lethality of zymosan-primed EAT 
bearing mice after the LPS injection. The reasons are not 
clearly known. It might be due to the reason that the large EAT 
burden weaken the healthy state of the mice. Therefore, the 
mice become more easy to die after the challenge of LPS. 
Similar phenomenon could also be observed in Fig.5.l0 (a). At 
the day of'LPS injection, the EAT cell number in mice 'was very 
little since only lxl04 EAT was used for inoculation. Only 10% 
of mice died due to endotoxin shock. The sulindac and 
mannoheptulose could completely protect the mice. Moreover, 
some mice had been completely cured after the induction of TNF. 
95 
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I n the case of 2xl0 1 EAT for inoculation (Fig.5.10 (b)), 60 % 
I 
I EAT bearing mice was also completely cured. In conclusion , for 
the effective and safe tre~tment of EAT bearing mice by in v ivo 
production of TNF, the EAT cell number bearing in mice mus t b e 
as little as possible during the TNF induction. In other words, 
the treatment is recommended to be taken at the beginning state 
in the turnor development but not in the advanced disease state. 
The TNF induced by LPS to result a hypothermic effect 
«35°C) in non-EAT bearing mice despite the sulindac and 
mannoheptulose were applied or not. Previous results discovered 
that TNF, IL-l (Anders and Terje 1988) could induce the 
hypothermic effect in mlce. The lowest mean temperature 
recorded after injection of 0.375 ug of Hr-TNF-a was 33.4°C. 
When Hr-TNF-a was combined with 0.5 ug/mouse of IL-1-a or IL-1-
~, the lowest mean temperature detected were 28.4°C and 31.6·C 
respectively. In another study, mice showed a dose dependent 
hypothermia after intravenous Hr-TNF injection (Bauss et 81 
1987). The hypothermic effect in mice seems to be caused by 
some factors which could not be eliminated by the combined 
application of sulindac and mannoheptulose. It is unlikely that 
IL-1 causes TNF-induced hypothermic effect because no IL-1 was 
detected in plasma of mice injected with Hr-TNF (Bauss et 81 
1987). The actual mechanism of hypothermic effect induced by 
TNF requires the further investigations. 
The EAT cells being applied is tumorigenic. After the 
implantation, the EAT cells grew rapidly. The increase in body 
weight of mice after implantation as shown in Fig. 5.5 is due to 
the increase of the amount of the cells number and ascitic fluid 
in these mice. Nine days after the implantation of 2xl0 5 EAT, 
. 96 
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t he total EAT cells number in mice was found to be 2x10 9 . As 
shown in Fig.5.6., the body weight of mice treated with zymo san 
and LPS on day 9 was less than that on day O. It is because TNF 
which is also called cachectin by its nature can induce 
cachexia. Cachexia, a frequent pathophysiological complication 
of malignancy, is 









(Beutler 1988 ) . TNF has numerous biological activities 
including the suppression of lipoprotein lipase (LPL) activity 
in adipocytes which is similar to that of LPS (Price et al 1986, 
Friedman et 81 1988, Porat 1989). Reduced LPL activity in 
plasma and adipose tissue correlates with, and may be 
responsible for, the hyperlipidemia and weight loss that are 
often observed in animals (Mahony and Tisdale 1988, Socher et 81 
1988). Moreover, the Hr~TNF has been shown to induce systemic 
side effects including anorexia in human (Feinberg et a1 1988). 
Treatment of mice with conditioned media from endotoxin-
activated macrophages which contains TNF (Cerami et a1 1985) or 
the injection of Hr-TNF (Mahony and Tisdale 1988) also reduces 
food intake, water intake and body weight. Therefore, it has a 
great deal evidences to support that TNF and LPS is the mediator 
of the cachexia in vivo and responsible for the weight loss in 




MODIFIED PROCEDURE FOR THE IN VIVO PRODUCTION OF 
TUMOR NECROSIS FACTOR FOR THE TREATMENT OF 
EHRLICH ASCITES TUMOR BEARING MICE 
INTRODUCTION 
Anti-turnor therapy by the induction of endogenous tumor 
necrosis factor (TNF) in human was recently reported (Mikio et 
81 1985). In our project, the in vivo production of TNF to 
treat the . EAT bearing mice was studied. The protocol of in vivo 
production of TNF using zymosan and LPS for the treatment of EAT 
bearing mice was described in the preVlOUS chapter. However, 
the result was far from satisfaction because the mice died 
rapidly and immediately due to the endotoxin shock of 
lipopolysaccharide (LPS). The life of these EAT bearing mice 
could not be prolonged. In addition, the EAT in the mice could 
not be completely killed by just one time induction of TNF. In 
this connection, Michael and Paul (1976) previously showed that 
LPS injected one day after the ascites turnor inoculation could 
protect the BALB/c mlce. In our previous study, it was 
suggested that TNF therapy on EAT bearing mice should be carried 
out at the beginning stage of the tumor development so that less 
lethality after the LPS injection could be obtained (Fig.5.8, 
Fig.5.9, Fig.5.10) In this chapter, we tried to modify the 
previous procedure in order to achieve a better and more 
effective one. We have tried to pre-treat the mice with zymosan 




Female ICR strain of mlce, about 35 g body weight, were 
used in all experiments. Zymosan was dissolved in PBS by 
sonication. Sulindac and D-mannoheptulose are products of 
Sigma. Mannoheptulose was dissolved in PBS. Sulindac was 
dissolved in PBS by sonication. 
On day 0, 2-9 rng zymosan per mouse was injected i.p .. On 
day 5, 2xl0 5 EAT per mouse were inoculated · l.p .. On day 6, 
sulindac, mannoheptulose and LPS were applied into the mice 
similar to that described in experimental in chapter 5. The 
mice were bled from subclavian vessels 2 h after LPS injection. 
The sera were pooled, heat inactivated at 56°C for t h, filter-
sterilized and stored frozen at -20°C until use. Control sera 
were obtained from EAT bearing mice. On -day 14, EAT of groups 
of at least 7 mice were collected by exhaustive drainage and 
I 
harvested by centrifugation. 
I 
I 
Pooled cells were washed once with 
half-PBS to remove erythro9ytes. The final cells suspension was 
prepared in PBS. Cells were counted ~ith a hemocytometer using 
0.3% trypan blue. Mortality of mice after the injection of LPS 





Mice received zymosan priming 5 days befo re EAT 
transplantation and LPS was injected on day 6. As shown in 
Fig.6.1, about 50% of these mice died immediately a f ter the 
injection of LPS. The TNS titre as measured 2 h after LPS 
injection were high in these zymosan primed EAT bearing mice. 
Moreover, sulindac and D-mannoheptulose could not alleviate the 
toxicity of LPS. However, as shown in Table 6.1, the remaining 
mice had not any EAT cell at all in their peritoneal cavities 
when the cell counts were performed 8 days after the LPS 
injection. Moreover, the remaining mice which could tolerate 
the toxic effects due to LPS injection remained survived over 
100 days after the zymosan injection (Fig.6.1). It may be 
because the EAT cell in their peritoneal cavities had already be 
~ 
completely killed. All control mice died 19 days after EAT 
inoculation. 
As shown 1n Fig.6.2, the EAT bearing mice treated with 5 
mg zymosan died more rapidly after LPS injection than that of 
the 2 mg · ·zymosan treated group. The EAT cells could not be 
completely killed in some of the remaining mice by this method 
I 
(Table 6.2). However, so~e treated mice still survived on day 
100 whereas all control mice died on day 26 (Fig.6.2). The TNS 
I 
titre of the 5 rng and 2 mg zymosan treated groups were also 
lower than that of 9 rng zymosan treated group (Table 6.1, Table 
6.2) 
Fig.6.3 showed that the result of another experiment using 
2 mg zymosan to prime the mice on day 0 and EAT transplantation 
on day 5 followed by LPS injection on day 6. The result of this 
experiment was coincident with the result in Fig.6.2. However, 
Chapter 6 
the LPS only injected one day after the EAT inoculation cou ld 
not prolong the life of EAT bearing mice even though LPS could 




TABLE 6.1 EFFECT OF IN VIVO PRODUCTION OF TNF BY 9 mg ZYMOSAN 




Zymosan and LPS 
Zymosan,SM,LPS 
bTumor number 
% of control 







a Groups of 30 mlce were injected with 9 mg zymosan on day O. 
2x10 5 EAT were inoculated on day 5. On day 6, LPS with or 
without sulindac and mannoheptulose were applied. bOn day 14, 
EAT cells were counted. cMice were bled 2 h after LPS injection. 
TNS titre was determined from pooled sera from 5 surviving mice 
in each group. 
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Fig.6.! Rate of mortality of EAT bearing mice of different 
treatments after LPS injection. Groups of 30 mice were injected 
9 mg zymosan on day O. On day 5, 2xl0 5 EAT were inoculated. On 
day 6, 25 ug LPS with or without sulindac 28 mg/kg body wt. 
orally and mannoheptulose 250 mg/kg body wt. subcutaneously were 
applied to mice. The mortalities of mice were monitored on the 
indicated days. (0)9 mg Zym, 2xl0 5 EAT, LPS; (e)9 mg Zym, 2xl0 5 
EAT,SM,LPS; (6)2xl0 5 EAT control. Abbreviations: Zym = Zymosan 





Table 6.2 EFFECT OF IN VIVO PRODUCTION OF TNF BY 2 rng OR 5 rng 
ZYMOSAN PRIMING AND THEN LPS INJECTION ON THE TUMOR GROWTH OF 
EAT BEARING MICE. 
a Treatrnent 
Control 
2 mg zym,SM,LPS 
5 mg zym,SM,LPS 
bTumor number 
% of control 
100 ± 12(n=8) 
o (n=3), 35 + 15*(n=5) 





aGroups of 30 mice were injected 2 mg or 5 mg zymosan on day o. 
On day 5, 2xl0 5 EAT were inoculated. On day 6, LPS & SM were 
applied. ban day 14, EAT cells were counted. Some mice of the 
treated groups had not any EAT at all during cell counting. 
cMice were bled 2 h after LPS injection. TNS titre was 
determined from pooled sera from 4 surviving mice in each group. 
The differences between the groups of treatments and control are 













































































































































































































































































































































































































































































Table 6.3 EFFECT OF IN VIVO PRODUCTION OF TNF BY 2 mg ZYMO SAN 
PRIMING AND THEN LPS INJECTION OR BY LPS INJECTION ALONE ON TH E 
TUMOR GROWTH OF EAT-BEARING MICE. 
aTreatment 
control 
25 ug LPS only 
2 mg zym,SM,LPS 
bTumor number 
% of control 
100 ± 6 (n=8) 
55 ± 15* (n=8) 





aGroups of 30 mice were injected 2 rng zymosan on day O. On day 
5, 2xl05 EAT were inoculated. On day 6, LPS & SM were applied. 
bOn day 14, EAT cells were countede Some mice of the zymosan 
and LPS treated groups had not any EAT at all during day 14 cell 
counting. cMice were bled 2 h after LPS injection. TNS titre 
was determined from pooled sera from 4 surviving mice in each 
group '. The differences between the treatment and control are 
determined by Student's t~test. *P<O.OOl. 
;,' :' : ~_:, 106 
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Chllpt er 6 
DISCUSSION 
I been reported that TNF causes necrosis o f certain 
I 
tumors in vivo (Carswell ~t 81 1975) and regresses certain k i nds 
of tumor cells in vitro (Watanabe et ' 81 1985, Palladino 1987, 
North 1988). However, the in vivo production of TNF for the 
treatment of tumor bearing mice has not yet reported. In our 
project, this topic was studied. The previous procedure for the 
TNF treatment of mice was discussed in chapter 4 and 5. In the 
modified method described in this chapter, zymosan was injected 
to mice before EAT inoculation and TNF was induced by LPS 
injection just one day after the EAT inoculation. This modified 
procedure was shown to be effective in killing all the EAT cells 
in some mice using 5 mg or 2 mg zymosan for priming (Table 6.2). 
In the case of 9 mg zymosan, even all the EAT cells in each 
mouse was completely regressed (Table 6.1). The reason of 
complete regression of EAT cells may be due to the effect of LPS 
which was injected just one day after the EAT inoculation. At 
that time, the EAT cells number is little enough so that TNF 
being produced can kill all of the EAT cells. 
We found that 5 mg or 2 mg zymosan were effective doses in 
this protocol. In the case of 9 mg zymosan, although all EAT 
cells in each mouse were completely killed, about 50% of the . 
mice died rapidly even the sulindac and mannoheptulose were 
applied (Fig.6.1). It may be due to the very high TNF being 
induced (Table 6.1). Since TNF is a mediator of cachexia 
(Beutler 1988). Results of many other phase I clinical trial 
als~ indicated that the amount of Hr-TNF being applied to 
patients must not be too high due to its systemic side-effects. 
TNF also has profound effects on the generation and activation 
": 108 
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of hematopoutic cells, 
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the function of the lffimune system 
effector cells, and the activation of the vascular/ coagu lation 
system (Beutler 1988). The maximum tolerance dose (MTD) of 
using Hr-TNF in human should be investigated. 
In Fig 6.3, the LPS injection one day after EAT cells 
inoculation in mice without zymosan priming could not prolong 
the life of these mlce even the LPS only kill some EAT cells on 
the day of cells counting. This result is not agreeable to the 
results of study of Michael and Paul (1976). They showed that 
when 20 ug LPS was injected l.p. into BALB/c mice one day after 
the i.p. injection of 4x10 3 TA3-Ha ascites tumors, turnor growth 
was prevented and the life of mice was prolonged. It may be due 
to the difference in the nature of animal and tumor model as 
well as the tumor number for the inoculation that these workers 
and we used. 
In conclusion, from our experiment model we found that in 
order to obtain good effectiveness of TNF on turnor treatment, 
TNF must be applied during the initial stage of the cancer 
disease. It is because the tumor burden is not large at that 
time and the effectiveness of TNF cytotoxicity is very high. 
The phase I clinical trials in human also pointed out that the 
Hr-TNF therapy were far from satisfaction in the advanced 
disease patients (Patrick 1989). Table 1.3 showed that only few 
advanced cancer pa~ients I had positive responses after the 
I 
intralesional application of Hr-TNF. In our study, this finding 
is also confirmed in the experimental : animal. In chapter 5, we 
have reported that the lethal effect of LPS was related to the 
EAT cell number in the mice during the induction of TNF. The 
large EAT cells number in mice induced a more serve lethal 
. ' . , 109 
effect after the LPS injection. Hence, 
Chapter 6 
the Hr-TNF should be 
applied in the beginning stage of cancer disease of patient s In 
the further clinical trial for a more efficient therapy. 
Finally, it must be emphasized that the modified procedure 
described in this chapter is not clinically relevant because the 
zymosan treatment was done before the EAT inoculation in mice. 
It is not very reasonable to prime a human being with high-risk 
of tumor suffering with some immunopotentiator (for example, 
zymosan in this case) before he is really attacked by tumor. It 
is just an artificial procedure to demonstrate the relationship 
between the in vivo effectiveness of the tumor killing effect of 





COMBINED TREATMENTS OF IN VIVO PRODUCTION OF 
TUMOR NECROSIS FACTOR (TNF) WITH HYPERTHERMIA, 
METHOTREXATE (MTX), POLYRIBOINOSINIC-
POLYRIBOCYTIDYLIC ACID (POLY I·C), N-(PHOSPHONACETYL)-L-
ASPARTATE (PALA) ON EAT BEARING MICE 
INTRODUCTION 
In the preVlOUS experiments, the in vivo production of TNF 
by single injection of zymosan and LPS could not completely cure 
EAT bearing mice. Moreover, the side-effects during in vivo 
production of TNF could not be completely eliminated by the 
I 
i 
combined treatment of sulindac and mannoheptulose in EAT bearing 
mice. Recently, attempts !have been made to test the anti-tumor 
effect of the combinations of TNF with various anti-cancer 
agents (Watanabe et 81 1988a) or ~-interferon (Williamson et 81 
1983, Aggarwal et 81 1985). Some recent findings indicated that 
good results without side effects could be obtained by systemic 
administration of Hr-TNF in combination with hyperthermia, with 
immunotherapy using Lentinan or OK 432, or with chemotherapy 
using cyclophosphamide and mitomycin C for the treatment of Meth 
A sarcoma bearing mice (Haranaka et 81 1987). We also 
investigate the therapeutic values of combined treatments of in 
vivo production of TNF by administration of zymosan and LPS with 
hyperthermia, MTX, poly IoC, PALA on EAT bearing mice. 
Hyperthermia is a new method for the clinical treatment of 
cancer. Hyperthermia might be used to treat cancer either alone 
or in combination with radiation or chemotherapy. The rationale 
of using hyperthermia to trea~ malignant disease is based on 
experimental studies which suggest that tumors may .be mor~ -
; 111 
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susceptible .to thermal injury than normal tissues ( Field and 
Bleehen 1979). One of the most remarkable characte r istics is 
the very fast ~xpression of molecular and metabolic alterations 
during or after heat treatment . While inhibition of DNA, RNA 
and protein synthesis is observed only several hours o r e ven 
days after x-irradiation (Streffer 1969), such effects already 
occur during heating of t~mor cells at 42°C - 43°C (Hahn 1982, 
Streffer 1982). Hyperthermia apparently induces conformat i onal 
changes in complex macromolecular structures like multienzyme 
complexes which lead to the inactivation of the biological 
function. These changes are important for the hyperthermic 
damage to membranes (Lepock et 81 1982,1983). 





reactions. As I a consequen1ce, a rapid turnover of metabolities 
occurs which is followed by disregulation (Streffer 1988). 
Hyperthermia .could inhibit DNA, RNA, protein synthesis (Panniers 
and Henshaw 1984, Fung et 81 1988b), the rate of glucose uptake 
as well as the density of glucose transporters on the cells 
(Fung et 811988b), ornithine decarboxylase activity (Matsui-
Yuas et 81 1989) in. the EAT. It has been known for quite some 
times that the action of various kinds of antitumor drugs is 
enhanced when they are administered in combination with 
hyperthermia in vitro (Tsumura et 81 1988, Neumann et 81 1988, 
Mizuno et 81 1980), : in animals (Overgaard 1976, Yarnada et 81 
1985) and in human (Maeta et 81 1987). Therefore, the 
therapeutic value of the combination of hyperthermia with in 
vivo production of TNF is valuable to be investigated. 
Methotrexate (MTX,2,4-diamino-NIO-methylpteroylglutamic 
acid) (Fig.7.A) is a widely used drug for the treatment o f 
1112 
s e veral human neoplastic diseases. It lS 
Chapter 7 
al s o an 
. . lmmunosuppresSlve agent. It is an analogue of the vitamin fo lic 
acid. MTX, as well as dichloro HTX, are "stoichiometric" 
inhibitors of the enzyme dihydrofolate reductase (DHFR) at pH 
6 . 0 . Dihydrofolate reductase is a key enzyme leads to the 
synthesis of thymidylate, purines and the amino acids serine and 
methionine (Bertino 1980)1 
I 
The inhibition of dihydrofolate 
reductase (DHFR) by MTX or its polyglutamate (MTX(Gn)) leads to 
a decrease 1n formation of tetiahydrofolate (FH4 ) , and 
subsequently a . decrease In purine, thymidylate (dTMP) 
biosynthesis and cellular replication. It lS because DNA 
synthesis and cellular replication lS important 1n rapidly 
proliferating tissue, cellular proliferation in malignant tissue 
is greater than that 1n most normal tissue and thus MTX may 
impair malignant growth more pronouncedly. 
F ulic acid 011 H 
r-, \c I hot re x J t c 
Fig.7.A 
There are three major antigenic types of interferons 
( I FN s ) . They have been shown to be a family of closely related 
proteins and glycoproteins. The original leukocyte-derived IFN 
1S called alfa (a) and fibroblast-derived IFN is termed beta 
(~). These two IFNs share the same recepto r . 
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Interferon (IFN-~) is structurally quite different and shares 
only the antiviral properties of the other IFNs. All these 
kinds of IFN8, and other cytokines as well, are pleiotropic i n 
their biological activities. All IFNs have antiviral properties 
and potent effects on t'he I immune system . . All IFNs have 
I 
antiproliferative properti'es, they can suppress the growth of 
both tumor cells and some normal cells. Moreover, they can 
affect cellular differentiation (Gutterman et 81 1988, Foon et 
81 1989). Polyriboinosinic-polyribocytidylic acid (poly r·c, 
Fig. 7 .B), a double-stranded polyribonucleotide, 18 a good 
interferon inducer (Gresser et 81 1978). It have been shown 
that poly l·C can arrest the growth of wide spectrum of tumors 
(Rhim et 81 1971, Fung et 81 1986) probably mediated by IFNs. 
N-(Phosphonacetyl)-L-aspartate (PALA) (Fig.7.C), an analog 
of the transition state for the aspartyl transcarbamylase and a 
potent and specific inhibitor of de novo pyrimidine 
biosynthesis, was · reported to have a considerable antitumor 
activity against certain transplantable tumors in mice (Johnson 
et 81 1978). PALA, unlike other antimetabolites, was less 
effective against ascites leukernias than against two solid 
turnors, B16 melanoma and Lewis lung carcinoma (Johnson et 81 
1976). PALA has been shown to suppress the growth of EAT in 
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Female ICR strain of mice, about 35g body weight, were 
used in all experiments. Zymosan was dissolved in PBS by 
sonication. Sulindac was dissolved in PBS by sonication at 5 
mg/ml. Mannoheptulose was dissolved in PBS at 45 mg/ml. 
Sulindac and mannoheptulose were applied to mice according to 
the experimental in chapter 5. PALA from National Cancer 
Institute was dissolved in PBS at 3.75 mg/ml. PALA at 0.75 mg 
in 0.2 ml PBS per mouse was injected i.p .. Poly l'e from Sigma 
was dissolved in distilled water at 10 mg/ml and frozen. It was 
diluted in PBS (pH 7.4) to the desired concentration before 
used. Poly I·e at 300 ug in 0.2 ml PBS per mouse was injected 
i.p.. Methotrexate from Sigma was dissolved in water at 0.681 
mg/ml by acidification by concentrated Hel. MTX was injected 
i.p. at 4 mg/kg in 0.2 ml on the indicated days post-
transplantation. 
Before the actual hyperthermia was performed, the normal 
mice were screened by placing them in a constant temperature 
room of 43°C for 1 h, the survived mice after the heat treatment 
were considered to be physically strong enough for the following 
hyperthermic treatment. During the hyperthermic treatment, EAT 
bearing mice were put into a constant temperature room of 43°e. 
After about 30 minutes, the body temperature of mouse increased 
to 41°e. The hyperthermia was last for 45 minutes at 41°C body 
temperature. The body temperature of mouse was monitored by an 
electronic thermocouple (YSI. Tele-thermometer) 
On day 0, EAT were inoculated i.p .. On day 1, zymosan was 
injected i.p.. On day 7, LPS was injected i.v.. Mice were bled 




Mate rials and Methods in chapter 3. 
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Se rum o f EAT bearing mice 
wa s used as control. On day 9, EAT cells of groups o f at least 
7 mice were collected by exhaustive drainage. Pooled c ell s were 
washed oncewi -th half-PBS to remove blood cells and harv e sted by 
centrifugation. The final cell suspension was prepared in PBS. 
Cell number was determined by a hemocytometer using 0.3 % trypa n 
blue. Groups of at least 20 mice were used for each survival 
test. 
MTX, PALA, Poly l·e and hyperthermia were applied on the 




During the hyperthermic treatment, the EAT bear ing mlce 
Here put into a 43°C warm room. The body temperature o f the 
mice raised from 37°C to 41°C within 30 minutes as shown In 
Fig.7.1. Hyperthermia treatment was obtained by further keeping 
the mice at 43°C warm room for 45 minutes. From Table 7.1, 
about 30% of these EAT bearing mice died during or after the 
first three times hyperthermia. The remaining mice could 
, 
survive through subsequent hyperthermia treatments till the 
seventh- and eighth- time hyperthermia during which LPS has been 
injected. Some mice died due to the endotoxin side effects. In 
order to keep mice survive throughout hyperthermia till LPS 
injection, a screening method should firstly be done to screen 
the normal mice which were strong enough during the subsequent 
hyperthermia . Prior study indicated that about 25 % of normal 
mice died under the screening process by keeping these normal 
mice at 43°C warm room for 1 h. The screened survived normal 
mice were transplanted with EAT and received the above same 
treatments seldom died throughout first to sixth hyperthermic 
treatments (Table 4.2). It indicated that the screening method 
I 
was useful. For later studies, normal mice after screened were 
used for testing the effect of hyperthermia and in vivo 
production of TNF on EAT growth. 
Table 7.3 shows that multiple hyperthermia could kill 
about 10% EAT while comparing with control on the day of EAT 
cell counting. The combined treatment of in vivo production of 
TNF and hyperthermia had an additive effect on the suppression 
of EAT cell proliferation. Hyperthermia dld not have 
significant suppressive effect on TNF production. In the 
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hyperthe r mia a lone could not 
prolong the life of EAT bearing mice while comparing with th e 
control. However, some mice of the TNF plus hyperthe r mi a group 
had life longer than the control and hyperthermic group. 
As shown in Table 7.4, the anti-turnor effect of t hree 
times MTX injection was higher than that of TNF. The MTX p lus 
TNF treatment had similar anti-turnor effect as that of MTX 
treatment alone. However, MTX injections could suppress the TNF 
release by about 7 folds. As shown in Fig.7.3, mice were 
inoculated with 2x10 5 EAT on day 0 and subjected to treatments, 
about 30% mice had been completely cured under the MTX plus TNF 
treatment 19 days after LPS injection whereas all control mice 
died on or before that day. As shown in Fig.7.4, mice were 
inoculated with 4x104 EAT ,on day 0 and subjected to treatments, 
.: ! 
I 
95% mice had '" been completely cured in MTX treated group. 
However, only 60% mice had 'been completely cured in the combined 
treatment. All control mice died on or before 17 days after LPS 
injection. 
Mice were inoculated with 2x10 5 EAT cells on day 0 and 
subjected to treatments. As shown in Table 7.5, poly r"e 
injected i.p. at 300 ug/mouse could possess anti-turnor effect. 
However, the anti-tumor effect of 100 ug poly I'C injected i.v : 
was not significant. Injection of poly lie alone could not 
produce any TNF titre in the serum of EAT bearing mice. The 
combined treatments of poly r · c (i.p.) and TNF possessed the 
additive anti-tumor effect on day 9. The injection of poly r"e 
to zymosan-primed and LPS elicited mice could not affect the TNF 
titre in these mice. As shown in Fig.7.5, mice were inoculat ed 
with 4x104 EAT cells on day 0, 50 % mice were completely cured 
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1n the poly l·e plus TNF treatment group 19 day s after LPS 
injection. 
As shown 1n Table 7.6, PALA alone or combined with TNF had 
an enormous anti-turnor effect on day 9. Some PALA-treated m1ce 
had no EAT cells 1n their peritoneal cavities on day 9. 
However, the TNF production of PALA treated mice was less than 
that of non-PALA treated mice. As shown in Fig.7.6, 80 % EAT 
bearing mice of 'the PALA treated and 50 % EAT bearing mice of 
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Fig.7.1 The body temperature of EAT bearing mice in a constant 
temperature room of 43°C. Values are expressed as mean ± S.D. 
for three experimental groups. 
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Number of mice 
died during 
HT treatment 




NUMBER OF EAT BEARING MICE DIED DU RING 
Day 1 Day 3 Day 5 Day 7 Day 8 
1st 2nd 3rd 4th 5th 6th 7th 8th 
2 0 0 000 1 2 
6 4 200 0 2 1 
The number of mice at the beginning of the experiment is 45. On 
day 0, EAT of 2x10 5 were inoculated into the mice. On day 1, 2 
mg zymosan was injected. On day 7, sulindac, mannoheptulose and 
25 ug LPS were applied. Hyperthermia was carried out on day 1, 
3, 5 (twice a day), day 7,8 (once a day). The 7th hyperthermia 
was carried out half an hour after the LPS injection. 
Hyperthermia treatment was obtained by keeping the mice at 43°C 
warm room for 75 minutes as described in Experimental. 
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Number of screened 
mice died during 
HT treatment 
Number of screened 
mice died after 
HT treatment 
Day 1 Day 3 Day 5 Day 7 Day 8 
1st 2nd 3th 4th 5th '6th 7th 8th 
o o o o o o 2 o 
1 o o o . 0 o o o 
The number of screened mice at the beginning of the experiment 
is 23. On day 0, EAT of 2x10 5 were inoculated into the mice. 
On day 1, 5 mg zymosan was injected. On day 7, sulindac, 
mannoheptulose and 25 ug LPS were applied. Hyperthermia was 
carried out on day 1, 3, 5 (twice a day), day 7, 8 (once a day). 
The 7th hyperthermia was carried out half an hour after the LPS 
injection. Hyperthermia treatment was obtained by keeping the 
mice at 43°C warm room for 75 minutes as described in 
Experimental. 
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% of control 
100 + 7.41 
82.7 ± 17.3* 
57.6 ± 8.37** 











13660 ± 11120 
7940 ± 12060 
aFor each experiment, groups of at least 20 mice were inoculated 
with 2x10 5 EAT on day O. On day 1, 2 mg zymosan was injected. 
On day 7, sulindac, mannoheptulose and 25 ug LPS were applied. 
ban day 9, EAT cells of each groups were counted from groups of 
8 mice. The hyperthermia was carried out on day 1,3,5 (twice a 
day), day 7,8 (once a day). Each hyperthermia was last for 45 
minutes at 41°C body temperature (i.e. keeping the mice at 43°C 
warm room for 75 minutes). CMice were bled 2 h after LPS 
injection. TNS titre was determined from pooled sera from 4 
surviving mice in each group. The above results of TNS titre 
are expressed as mean ± S.D. of four individual experiments. 
The differences between the control and the group of treatments 
were determined by Student's t test. *P<O.01. **P<O.001. 
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Fig.7.2 Survival of screened EAT bearing mice under in vivo 
production of TNF and hyperthermic treatment. On day 0, 2x10 5 
EAT was inoculated. On day 1, 2 mg zymosan was injected. On 
day 7, sulindac and mannoheptulose and 25 ug LPS were applied. 
Hyperthermia was carried out on day 1,3,5 (twice a day), day 7,8 
(once a day). Each hyperthermia was last for 45 minutes at 41·C 
body temperature by keeping the mice at 43·C warm room for 75 
minutes.. (0) EAT control; , (0) EAT,HT,Zym,SM,LPSj (O)EAT,HT. 





TABLE 7.4 EFFECT OF IN VIVO PRODUCTION OF TNF AND THE 







% of control 
100 ± 18.7 
39.5 ± 18.q* 
9:4 + 15.3* 
9 . 4 ± 4. 8* 
CTNS titre 
o 
15850 ± 200 
o 
2180 ± 330 
aOn day 0, 2x10 5 EAT w~re inoculated into the mice. On day 1, 5 
mg zymosan was injected. On day 7, sulindac,mannoheptulose and 
25 ug LPS were applied. bOn day 8, EAT cells were counted from 
groups of 8 mice. The MTX at 4 mg/kg was injected into each 
mice i.p. on day 2,4,7. cMice were bled 2 h after LPS injection. 
TNS titre was determined from pooled sera from 4 surviving mice 
in each group. The differences between the treatment and 
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DAYS 'AFTER -LPS INJECCTION 
, 
:Fig.7.4 Stirvival test of EAT bearing mice after in vivo 
production of TNF and the application of MTX. On day 0, 4x10 4 
' EAT cells per mouse were inoculated. On day 1, 2 mg zymosan per · 
. mouse was injected. On day 7, sulindac, mannoheptulose and 12.5 
. ug LPS were applied. MTX at 4 mg/kg was injected i.p. once a 
day from day 1 until all the control EAT bearing mice died (i.e. 




TABLE 7.5 EFFECT OF IN VIVO PRODUCTION OF TNF AND THE 




Poly I· C (i. p. ) 
. , 
Po 1 y I - C (i. v. ) 
Zym,poly I-C (i.p.),LPS 
bTumor number 
% of control 
100 ± 25.4 
43.6 ± 13.8* 
68.3 ± 1.9** 
68.5 ± 23.8*** 
40.5 ± 19.7**** 
CTNS titre 
o 
3800 ± 300 
o 
o 
2800 ± 600 
·On day 0, 2xl05 EAT were inoculated into each mouse. On day 1, 
5 mg zymosan was injected. On day 7, sulindac, mannoheptulose 
and 25 ug LPS were applied. Poly I-e was applied i.p. at 300 
ug/mouse or i.v. at 100 ug/mouse on day 2,4,7. bOn day 9, EAT 
cells were counted from group ~ 8 mice. cHice were bled 2 h 
after LPS or poly I-C injection. TNS titre was determined from 
pooled sera from 5 surviving mice in each group. The 
differences between control and the groups of treatments were 
determined by Student's t-test. *P<O.001, **P<0.05, ***P<O.l, 
****P<0.005. 
, .' , ' ; . 
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DAYS AFTER LPS INJECTION 
Fig.7.5 Survival test of EAT bearing mice after in vivo 
production of TNF and the application of poly I' C. On day '·0, 
4xl0 4 EAT were inoculated. On day 1, 2 mg zymosan was injected. 
On day 7, sulindac and mannoheptulose and 12.5 ug LPS were 
applied. Poly r·c was injected at 300 ug/mouse once per 48 h 
until all the EAT bearing mice died (i.e. 19 days after LPS 




TABLE 7.6 EFFECT OF IN VIVO PRODUCTION OF TNF AND THE 








% of control 
100 ± 27.6 
49.5 ± 20.0* 
0.5 ± 1.0** 






aoo day 0, 4xlO. EAT were inoculated into each mouse. · On day 1, 
2 mg zymosan was injected. On day 7, sulindac, mannoheptulose 
and 12.5 ug LPS were injected. PALA was injected i.p. at 20 
mg/kg from day 1 to 8. bOn day 9, EAT cells was counted. CMice 
were bled 2 h after LPS or PALA injection. TNS titre was 
determined from pooled sera from 5 surviving mice in each group. 
The differences between the group of control and the treatment 
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DA YS AFTER LPS INJECTION 
Fig.7.6 Survival test of EAT bearing mice after in vivo 
production of TNF and the application .of PALA. On day 0, 4x104 
EAT were inoculated. On day 1, 2 mg zymosan was injected. On 
day 7, sulindac and mannoheptulose and 12.5 ug LPS were applied. 
PALA was injected at 20 mg/kg once a day until" all the EAT 
bearing mice died (i.e. 19 days after LPS injection). (O)EAT 
control; (e)EAT,PALAj (~)EAT,Z~~,PALA, SM,LPS 
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DISCUSSION 
TNF is an anti-canc~r monokine with demonstrat ed in vi tro 
cytotoxicity against cultural cell lines (Carswell et s1 1975, 
Watanabe et s1 1985, North and Havell 1988). It has reported 
that elevated temperatures (40·C) enhance the sensitivity of L-M 
cells to TNF-containing serum (TNS) by 15 folds (Frederick and 
Pedro 1981). The explanation had been proposed that the 
.internalization is required for the mechanism of in vitro 
cytotoxicity of TNS towards tumor cells. The temperature 
facilitates the penetration of TNF into target cells. Some 
recent discoveries also proved that Hr-TNF and hyperthermia 
exert synergistic effects on cytotoxicity and anti-turn~r effects 
in vitro (NUtsu et s1 1988, Dubois et s1 1989) and in vivo 
(Haranaka et sI 1987, Watanabe et sI 1988c). However, only 
additive anti-tumor effect of these combined treatment was found 
in our experimental model. Our method made use of the 
administration of zymosan and LPS for the in vivo production of 
TNF in EAT bearing mice and then treated with hyperthermia was 
quite different from that of using Hr-TNF and hyperthermia in 
Meth-A fibrosarcoma as reported by Watanabe et s1 (1988c). Some 
. 
EAT bearing - mice of the group of . combined treatment in our 
study had ' prolonged life than that of the group of control or 
single treatment (Fig.7.2). One of the interesting finding 
about~ the relationship between TNF and ~emperature was 
discovered in recent research. Heat shock treatment at 41·C on 
WEHI-164 fibrosarcoma cells significantly (and transiently) 
decreases the sensitivity of these cells to Hr-TNF mediated 
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lysis and diminished the lytic potential of inflammatory T c ells 
by arresting their secretion of TNF (Gromkowski et a1 1989). 
Heat shock could induce (or increase) the synthesis of a 
regulatory protein(s) that interferes with the intracellular 
transduction of the cytolytic TNF signal or protect the cell 
from changes induced by TNF. In our method, hyperthermia were 
applied on EAT bearing mice in vivo for several times before the 
induction of TNF. Hyperthermic treatments do not affect much on 
the TNF release in these mice (Table 7.3). However, the effects 
of hyperthermia on the immune system, physiological state, TNF 
secretion in mice and heat shock proteins synthesis in EAT cells 
. 
in vitro and in vivo await further investigation. More works 
must be done to clarify the effect of in vivo production of TNF 
and hyperthermia on this experimental model. The -method of 
using warm room for the hyperthermia treatment has many 
advantages. Firstly, · the mice need not anesthetize by sodium 
pentobarbital or secobarbital sodium. The treatment of 
anesthetization caused some mice died during the hyperthermia. 
Secondly, screening method can be used to select the strong mice 
for the hyperthermia. Finally, the set up of the warm room is 
very simple. 
MTX is a widely used drug for the treatment of many human 
cancer such as leukemia. As a result of inhibition of the 
thymidine monophosphate synthesis by MTX, cells are unable to 
synthesize sufficient DNA for subsequent division. At a 
critical point, cells death ensures, but the exact reason for 
cell death is not clear. This type of cell death has been 
referred to as "thymineless" death and results in what has also 
been referred to as unbalanced growth (Bertino 1981). Besides, 
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HTX has been shown to be at least in part attributable to its 
ability to inhibit the rate of cellular glucose consumption 
(Kaminskas· 1979). Thus, Kaminskas and Nussey showed that HTX 
markedly reduced glycolysis in cultured EAT cells (Kaminskas and 
Nussey 1978). Kaminskas further demonstrated that this 
reduction was the result of decreased hexose uptake although the 
inhibition of sugar phosphorylation has also been implicated. 
Chan et s1 (1983) showed that.MTX inhibited glucose consumption 
in EAT by decreasing the glucose uptake with lowering the 
glucose carrier number but not the affecting structure of the 
carriers. In our study" repeated i.p. injections of HTX of 4 
mg/kg was shown to be the most effective way to cure EAT bearing 
mice. In the case of 4xlO· EAT for inoculation, about 95 X EAT 
bearing mice had been completely cured. However, the 
therapeutic effect of combined treatment was far from 
. satisfaction because only about 60% EAT bearing mice had been 
completely cured (Fig.7.3). MTX is an immunosuppressive agent 
such that the administration of MTX can suppress the 
reticuloendothelial system as well as the TNF production (Table 
7.4). However, the reason of the low therapeutic effect of 
combined treatments is still unclear. The effectiveness of TNF 
and MTX treatment on mice inoculated with 4x10. EAT was better 
than that in mice inoculating with 2x105 EAT : cells (Flg.7.3, 
7.4). It supported again our previous finding that the TNF 
treatment must be carried out at an early stage of tumor 
development in order to obtain better effectiveness. 
Administration of poly l-e into EAT bearing mice could 
induce relatively low but constant titres of interferons (Fung 
et a1 1986). The · anti-turnor activity of poly l·e in our EAT 
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model is 'possible mediated by the induction of interferons. 
Many reports proved that the combined treatment of gamma-
interferon (gamma-IFN) and TNF had ~ synergistic effect on tumor 
cytotoxicity (Williamson et a1 1983). It has been suggested 
that a gamma-IFN dependent increase in TNF receptor expression 
underlies this synergy, but interaction has subsequently been 
shown to occur even when there is no change in TNF receptor 
expres~ion (Aggarwal ·et a1 1985, Ruggiero et s1 1986). However, 
only additive effects of TNF and poly I·C were found in our 
model. It may be because during the production of TNF in EAT 
bearing mice in our model, the IFN titre in the body of these 
mice may be very' low since the TNF and IFN were not induced at 
the same time. A synergistic effect of anti-tumor may occur if 
the LPS and poly I·C are injected at the suitable time for the 
induction of both the cytokines simultaneously. Poly l·e was 
shown to suppress the glucose carriers in the cells (Fung et a1 
1986). However, it is difficult to determine whether the 
Buppression in EAT cell growth is mediated through interferon in 
our model. 
PALA has been shown to arrest the growth of a wide 
spectrum of tumors (e.g. HT29, HeTS, L1210 and P388 leukemia) 
(Baillon et a1 1983, Johnson et s1 1976) and to reduce the rate 
of glucose utilization in one line of human cancer (HT29) cells 
(Jsuboi and Kwong 1978). PALA was found to inhibit the growth 
of EAT in vivo effectively in a dose dependent manner (Leung et 
a1 1984). PALA was also found to decrease the glucose carrier 
number but not affecting the structure of carriers in EAT (Leung 
et a1 1984). Fr·om our results, both repeated administration of 
PALA and combined treatment with in vivo production of TNF could 
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completely cure some EAT bearing mice (Fig.7.5). 
Up to the - present, clinical effects of clinical trials 
have been carried out in all over the world by using Hr-TNF on 
cancer patients. However, the therapeutic effects were far from 
satisfaction, only few cases have positive results (Frei and 
Spriggs 1989). However, it is too early to conclude that TNF 
does not have clinical antitumor potential. Efforts were taken 
\ 
to find several ways to define the treatment modalities to 
improve the anti-tumor effect of TNF clinically. The combined 
treatments of TNF with other cytokines (e.g. IL-2, gamma-IFN) 
or other chemotherapeutic agents (e.g. MTX, poly I-C, . PALA or 
other treating method such as hyperthermia) are one of the 
possible methods for trial. Our studies provide basic findings 
of several possible combined treatment methods in experimental 
animal . for this clinical trial. From the results of combined 
treatments of in vivo production of TNF with hyperthermia, MTX, 
Poly I-C and PALA, we found that MTX, poly I-e, PALA are good 
candidates for the further application of clinical trials in 
combined treatment with TNF. It is because all of them can 
completely cure some of the EAT bearing mice alone or when 
combined with TNF. Though the results are encouraging, the 
route and dosage for the application,of these drugs need further 
modifications to improve the effectiveness. Since hyperthermia 
is still a very new therapeutic method, whether it can be used 
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In the previous studies, we have shown that EAT cells is 
one of- the most susceptible cell lines to TNF. EAT cells could 
be killed by 1% TNF containing serum (TNS) after 8 h of 
" 
incubation in vitro and complete suppression was observed by 24 
h incubation (Ha et 81 1985a). Exposure of EAT cells to TNS for 
as little as 4 h t6tally abolished the transplantability of the 
. turnor. At the same time, the rate of glucose uptake and extent 
of, leucine incorporation were significantly reduced (Fung et a1 
1985). 
In my previous studies, it was found that in vivo 
production of TNF by zymosan and LPS could suppress the 
proiiferation of EAT in mice. However, the actual mechanism of 
the action of TNF on turnor cells was unknown. · Many other 
reports suggested that TNF can exert direct effects as well as 
indirect effects on turnor cell growth (Review see Old, 1988). A 
number of mechanisms have been suggested for the direct killing 
process of turnor cells by TNF, including free hydroxyl radicals 
generation (Yarnauchi et 81 1989) as well as release and 
activation of lysosomal enzyme in the turnor cells (Sakurai et a1 
1985, Haranaka 1988). Whatever mechan~srn is responsible, 
fragrnen~ation of cellular DNA of turnor cells is a nonspecific 
indicator of responsiveness to TNF (Berish et 81 1988,1989). 
Many previous studies indicated that the depletion of 
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nu c l e otides and the consequent inhibition of DNA , RNA and 
protein synthesis of tumor cells (Fung et 81 1988b) might have 
constituted the primary chain of events leading to the cell 
death. Therefore, the effects of in vivo production of TNF by 
zymosan and LPS on DNA, RNA, protein synthesis in EAT cells were 
investigated in this study. 
Tumor cells depend primarily on the catabolic breakdown of 
glucose for the energy. It is essential that tumor cells should 
possess a highly efficient system for the transport of glucose 
into the cell to metabolize it. Previous studies iri our group 
(Chan et 81 1983) have shown that the ability of EAT cells to 
take up glucose increased progressively during the course of 
tumor development and as the rate of uptake of glucose in tumor 
cells rose, the surface density of glucose 9arriers also 
increased simultaneously. This enhancement of glucose uptake by 
cancer cells during tumor growth, through increase in the number 
of glucose ' carriers, constitute the primary cause of 
hypoglycemia seen in cancer patients or tumor bearing 
experimental animals. 
In the studies of chemotherapy of EAT cells, it has been 
shown th~t methotrexate (Chan et 81 1983), N-(phosphonacetyl)-L-
aspartate (Leung et 81 1984) and interferon inducers (Fung et 81 
1986) can suppress EAT cells growth and simultaneously suppress 
glucose transport by decreasing the density of 'glucose carriers 
on the tumor cell surface. In this connection, since we have 
shown that TNF production in vivo can suppress EAT cells growth 
in mice, the effect of thisTNF so produced on the glucose 
I 
uptake in EAT cells was of interest to investigate. 
I 
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Female ICR strain of mice, about 30-35g body weight, were 
used in all experiments. Zymosan was dissolved in PBS by 
sonication. On day 0, 2xl05 EAT per mouse were inoculated i.p .. 
On day 1, 5 mg zymosan was injected i.p .• On day 7, 
in 0.2 ml'PBS was injected i.v .. Some mice were 
25·ug LPS 
bled from 
subclavin vessels 2 h 
thymidine, 3H-uridine, 
uptake experiment, some 
after LPS injection. For the 3H-
14C-leucine incorporations and glucose 
mice were killed and EAT cells were 
obtained after certain time intervals of LPS injection. 
Effect of in vivo production of TNF on 3B-thymidine, 3H-uridine, 
14C-leucine incorporations of EAT Cells 
The method of Fung et a1 (1988b) was followed with minor 
modifications. For measuring thymidine, uridine and leucine 
incorporation, EAT cells taken from mice at the indicated times 
after LPS injection were washed with half-PBS and resuspe~ded 
with fresh complete RPM! 1640 supplemented with 10 % heat-
inactivated fetal calf serum (HIFCS) to 1x106 cells/ml. One 
hundred ul cell suspension were added into test tubes and then 
mixed with 10 ul 3B-thymidine (50 uCi/ml), 3H-u~idine (50 
uCi/ml) or 14C-Ieucine (5 uCi/ml). After incubation at 37·C for 
certain period of times for 3H-thymidine, 3H-uridine or 14C-
leucine incorporations, the reaction was stopped with 1 ml cold 
5% TCA. The cells were then sonicated for 10 seconds. The 
sonicated cells were harvested with 5 ml ice cold 5 X TCA 
through GF/C filter by a cell harvester. The filters were 
subsequently washed with 5 ml 5% TCA and 10 ml ice cold absolute 
ethanol. Filters were dried in oven and placed in scintillation 
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scintillant. The 
r adioactivities were measured by a Beckman LS -1 80 1 liqu i d 
scintillation counter. Background absorption of radio a c tivity 
was corrected by addition of radioactive precurs ors after 
incubation and immediately before the harvest of cells. 
Effect of TNF production on Glucose uptake of EAT cells 
The method of Fung et 81 (1988b) was followed. EAT cells 
were taken out from EAT bearing mice at the indicated times 
after the ' LPS injection. The EAT cells were then washed with 
half-PBS for 3 times to remove the erythrocytes. For studying 
2-deoxy-D-[3H]-glucose uptake, EAT cells suspension (2x10 7 /ml in 
PBS) were equilibrated to 37°C. At zero second, 0.2 ml cell 
suspension was mixed with 0.2 ml pre-warmed 2-deoxy-D-[3H]-
glucose. Reaction was stopped after 6 sec. by transferring 0.2 
ml of mixture to 1 ml ice-cold PBS supplemented with 40 mM 2-
deoxy-D-glucose. Cells were collected . by centrifugation at 
15,000 x g for 10 sec. in an Eppendorff 5414 microcentrifuge. 
The supernatant was removed and the cells were washed with 1 ml 
of the same buffer. Cell lisis was accomplished by the addition 
, 
of 0.2 ml 0.1 % triton x-ioo. Triton X-toluene scintillant of 
I 
1.25 ml was added and the radioactivity was counted in a Beckman 
LS-1801 liquid scintillation counter. Non-specific diffusion 
was corrected by subtracting the uptake ·in the presence of 10 uM 




In Fig.8.1, a significant incorporation of 3H-thymidine 
can be obtained after about 3 h incubation of EAT cells with 
thymidine. Fig.8.2 shows that the 3H-uridine incorporation 
reached the plateau after about 5 h incubation of cells with 
uridine. Fig.8.3 shows that a significant incorporation of 14C-
leucine can be obtained after about 6 h incubation of EAT cells 
with leucine. Hence, 3 h, 5 hand 6 h incubation intervals for 
3H-thymidine, 3H-uridine and 14C-leucine respectively were 
chosen before the incorporation reactions were stopped for 
measuring the radioactivities in the cells. Fig.8.4 indicated 
that the in vivo production of TNF inhibited the 3H-thymidine 
and 14C-leucine incorporations significantlY . without changing 
the 3H-uridine incorporation significantly. MTX inhibited the 
3H-thymidine, 3H-uridine and 14C-leucine incorporations in EAT. 
However, the combined treatment of TNF and MTX inhibited all of 
the 3H-thymidine, 3H-uridine, 14C-leucine incorporations 
significantly. Fig.8.5, 8 • 6 , 8.7 indicate that in vi,vo 
production of TNF had not exerted any effect on glucose uptake 
I 
of EAT cells after LPS inpection of 48 h (Fig.8.5), 24 h 
I 
(Fig.8.6), 1 h (Fig.8.7) ~ and 0.5 h (Fig.8.7) tested at deoxy-
glucose concentration of 1 mM. Fig;8.8 shows that in vivo 
production of TNF after 14 h also did not exert ant effect on 
glucose uptake of EAT cells at deoxy-glucose range at 0.0-4.0 
mM. 
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Fig.8.1 Time course of 3H-thymidine incorporation into DNA in 
EAT cells taken from EAT bearing mice. On day 0, 2xlOs EAT 
cells were inoculated in mice. EAT cells were taken out from 
the EAT bearing mice 8 days after EAT cells inoculation. The 
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Fig.8.2 Time course of 3H-uridine incorporation into RNA in EAT 
cells taken from EAT bearing mice. On day 0, 2xlO s EAT cells 
were inoculated in mlce. EAT cells were taken out from the EAT 
bearing mice 8 days after EAT cells inoculation. The 
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Fig.8.3 Time course of 14C-leucine incorporation into protein in 
EAT cells taken from EAT bearing mice. On day 0, 2xlOs EAT 
cells were inoculated in mice. EAT cells were taken out from 
the EAT bearing mice 8 days after EAT cells inoculation. The 
incorporations of 14C-leucine were stopped at the indicated 
times. 
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Fig.8.4 Effect of TNF and MTX treatments on the synthesis of 
DNA, RNA and protein of EAT in EAT bearing mice. On day 0, 
2xl0 5 EAT were inoculated. On day 1, 5 mg zymosan was injected. 
On day 2,4,6, 4 mg/kg MTX was injected into these mice. On day 
7, 25 ug LPS was injected. The thymidine, uridine and leucine 
incorporations were done 18 h after LPS injection. TNF 
treatment referred to mice injected with zymosan and LPS. HTX 
treatment referred to mice injected with HTX only. Bars are 
mean ± S.D. for 3 determinations. The differences between the 
control and the groups of treatments are determined by Student's 
t-test. * P<O. 02. 
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Fig.8.5 Effect of in vivo production of TNF on glucose uptake of 
EAT cells at. 1 mM ' 3 H-DOG at 48 h after LPS injection. On day 0, 
2xl0 5 EAT were inoculated. On day 1, 5 mg zymosan was injected. 
On day 7, 25 ug LPS was injected. EAT cells were taken from 
mice 48 h later and the glucose uptake rates of EAT cells were 
determined. Bars are mean ± S.D. for eight determinations. 
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Fig.8.6 Effect of in vivo production of TNF on glucose uptake of 
EAT cells at 1 mM 3H-DOG at 24 h after LPS injection. On day 0, 
2xl0 5 EAT were inoculated. On day 1, 5 rng zymosan was injected. 
On day 7, 25 ug LPS was injected. EAT cells were taken from 
mice 24 h later and the glucose uptake rates of EAT cells were 
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Fig.8.7 Effect of in vivo production of TNF on glucose uptake of 
EAT cells at 1 mM 3H-DOG at t h or 1 h after LPS injection. On 
day 0, 2x10s EAT were inoculated. On day 1, 5 mg zymosan was 
injected. On day 7, 25 ug LPS was injected. Half or 1 h later, 
EAT cells were taken from mice and the glucose uptake rates of 
EAT cells were determined. Data are expressed as mean ± S.D . . 
for three determinations. 
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Fig.8.8 Effect of in vivo production of TNF on glucose uptake of, 
EAT cells at various concentration of 3H-DOG at 14 hours after ' 
LPS injection. On day 0, 2x10 5 EAT were inoculated. On day 1, 
5 mg zymosan was injected. On day 7, 25 ug LPS was injected. 
EAT cells were taken from mice 14 h later and the glucose uptake 
rates of EAT cells were determined. Data are expressed as mean 
± S.D. for three determinations. (e)Control EAT; (A)EAT taken 
from mice 14 h after LPS injection. 
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DISCUSSION 
It has been reported that TNF causes necrosis of c ertain 
tumors in vivo (Carswell et 81 1975, North and Havell 1988) and 
regresses various kinds of tumor cells in vitro (Watanabe et 81 
1985). TNF has been found to be an important immunomodulator. 
In the previous studies, TNF has been demonstrated to activate 
macrophages both in vitro and ~n vivo (Mace et 81 1988) and 
lncrease a mixed lymphocytes response and act as an adjuvant for ' 
both T- and B- cells in vivo (Talmadge et 81 1988). In 
addition, TNF can activate natural killer (NK) cells (Mannel et 
81 1989) and induce the production of interleukin 1 (IL-1) 
(Dinarello et 81 1986). IL-1 has been shown to regulate several 
immunol?gic functions. TNF shares many biologic properties with 
IL-1 (Le and ' Vilcek 1987). It was found that Hr-TNFa, like 
human IL-1~, ,was able to enhance the immune response to a T 
cell-dependent antigen (Ghiara et 81 1987). On the other hand, 
a number of mechanisms of TNF direct cytotoxicity have been 
proposed, they includes free radicals generation (Yamauchi et 81 
1989,), release of lysosomal, enzyme (Sakurai 1985, Haranaka 1988) 
I 
and DNA fragmentation (Beri:sh et 81 1988, 1989). 
I 
From the resul ts o:f present' study of TNF action on EAT 
cells, in vivo production of TNF in ' EAT bearing mice could 
inhibit the DNA and protein synthesis of EAT cells. This 
phenomenon was likely due to the TNF direct cytotoxic effect 
because TNF was found in the ascitic fluid (Fig.4.6). TNF 
mediated immune mechanism might also take part for the 
suppression of the proliferation of EAT cells in mice. TNF can 
induce DNA fragmentation in the target cells (Berish et 81 
1988,1989), hence, the induction of TNF could suppress the DNA 
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and the subsequent protein synthesis. TNF containing s erum 
(TNS) obtained from bacteria-primed and LPS injected normal mice 
has been reported to inhibit the growth of EAT in vitro and in 
vivo (Fung et s1 1985). The inhibition of EAT growth is likely 
through the inhibition of DNA synthesis due to the DNA 
fragmentation. Effect of in vivo production of TNF on the 
inhibition of RNA synthesis in EAT was less significant in our 
experiment. Previous studies indicated that mouse TNS could 
increase the 3H-uridine uptake of L929 cells (Fung et 81 1987). 
An increase in 3H-uridine uptake can be explained by the fact 
that some repairing mechanisms are undergoing in order to 
compensate the damages caused by TNF (Creasey et s1 1987). This 
means that inhibition of tumor growth is not necessarily caused 
by an inhibition of RNA synthesis. 
MTX is known to be a DNA, RNA, protein synthesis inhibitor 
(Hrynuik 1972, McBurney and Whitmore 1975). Therefore, HTX only 
and the combined application of MTX with the induction of TNF 
exerted the inhibition of DNA, RNA and protein synthesis. The 
combined applications of MTX and in vivo production of TNF were 
previously shown to result an additive effect on the suppression 
of the proliferation of EAT in mice. Therefore, it was expected 
that the combined treatment exerted the most potent inhibition 
of " the DNA, RNA and protein synthesis. 
In the previous studies, the TNS could inhibit the glucose 
uptake of EAT in vitro by decreasing the number of glucose 
carriers (Fung et s1 1985). However, the in vivo production of 
TNF had not any effect on the rate of glucose uptake after 1 h, 
1 h, 14 h, 24 hand 48 h of LPS injection (Fig.8.5, B.S t 8.7 and 
8.8). This discrepancy of results might be due to the low 
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glucose level in serum and ascitic fluid (Table 5.3) caused by 
the hypoglycemic effect induced by LPS (Witek -Janusek a nd 
Filkins 1983) and TNF (Evans et al 1989). Fung et a1 (1986) 
showed that the fall in serum glucose level induced by fasting 
or the application of insulin in mice enhanced the transport 
activity of glucose by increasing the glucose carriers in EAT. 
Although TNF produced could inhibit the DNA as well as the 
protein synthesis in our experiments, the EAT cells were induced 
an adaptable response for increasing the glucose transport 
activity to the fall in serum glucose level. As a result, the 
glucose uptake rate of EAT in mice could not be lowered by the 




SIDE EFFECTS OF TUMOR NECROSIS FACTOR AND 
LIPOPOLYSACCHARIDE ON RAT IN VITRO and IN VIVO 
INTRODUCTION 
Turnor necrosis factor (TNF) is originally discovered by 
Carswell et 81 (1975) to be a protein produced by mononuclear 
phagocytes that can cause hemorrhagic ~ecrosis of certain tumors 
I 
in animals. Most recently~ TNF is shown to be identical to 
cachectin which mediates c~chexia in cancer patient (Beutler and 
Cerami 1986). TNF is also termed as cachectin by many workers. 
TNF {cachectin} has been suggested to signal the °loss of the 
body weight, the decrease in adipose tissue and muscle mass, and 
anorexia during infections or chronic illness including cancer 
(Cerami et 81 1985, Mahony and Tisdale 1988, Flores et 81 1989, 
Balkwill et 81 1987). After the administration of recombinant 
human tumor necrosis factor (Hr-TNF) in human, the weight loss 
and anorexia are accompanied by accelerated muscle proteolysis 
and adipose-tissue lipolysis, and by increased ,hepatic rates of 
fatty acid oxidation and gluconeogenesis from lactate, amino 
acids and glycerol (starnes et 81 1988). The cachexia has been 
suggested to occur at least in part through the influence of the 
hormone on adipose tissue metabolism (Beutler 1989). 
Recombinant human tumor necrosis factor (Hr-TNF) can result in a 
dose and time-dependent suppression of the activity of 
lipoprotein lipase (LPL) in the fully differentiated 3T3-Ll 
adipocytes (Swiss albino mouse embryo fibroblasts differentiated 
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a d i pocytes) (Price et 81 1986). Chapter 9 This loss of lipopro tein l ipase 
activity in 3T3-L1 adipocytes exposed to either crude or highly 
purified preparations of TNF (cachetin) is due to a dire c t 
effect on the synthesis ofl the enzyme. It 1S demonstrated by a 
decreased 
I 
incorporation of methionine into 
immunoprecipitated lipoprotein lipase (Price et 81 1986). 
Experiment . further demonstrated that Hr-TNF reversibly down-
regulates LPL mRNA in fully differentiated 3T3-L1 adipocytes 
(Cornelius et 81 1988). Some research groups also found that 
the increase in serum triacylglycerol in the Hr-TNF treated rats 
probably mediated by an increased secretion of triacylglycerol 
by the liver (Chajek-Shaul et a1 1989) 
Lipopolysaccharide (LPS, endotoxin) 1S the component of 
the outer cell membrane of Gram negative bacterial (e.g. 
Escherichia coli). LPS has many biological effects similar to 
those of TNF (Bauss et a1 1987). For example, LPS also mediates 
the cachexia in the body. When LPS is injected into the body, 
it can cause the gross imbalance of the host metabolism, 
including hypoglycemia and hypertriglyceridaemia (Shands et a1 
1969, Waitek-Kawakami and Cerami 1981, Janusek and Filkins 
1983). LPS can also decrease the lipoprotein lipase activity in 
vitro or in vivo (Kawakami and Cerami 1981). 
In this experiment, purified Hr-TNF and LPS were used to 
investigate their effect on lipolysis in isolated rat 
adipocytes. The results ~an be used to determine if Hr-TNF and 
LPS act in non-time-dependent manner analogous to catabolic 
hormones (epinephrine). Moreover, the side-effect of in vivo 
production of TNF in rat by using zymosan and LPS were also be 
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The recombinant human TNF (Hr-TNF) was generously provided 
by Genentech (San Francisco, CA, U.S.A., TNF-a, lot no~G11038, 
L9009AX, containing 2.5X107 units/ml, 0.5 mg/ml). 
Lipopolysaccharide (LPS, Salmonella typhimurium) was purchased 
from Sigma. Hr-TNF and LPS were dissolved in PBS. Epinephrine 
was dissolved in ascorbic saline (pH 7.4). The method of 
measuring lipolysis was adopted from that of Butcher (Butcher et 
81 1968). Epididymal fat tissues were obtained from male 
Sprague-Dawley rats (160 g-190 g) and immersed in Krebs Ringer 
Buffer. Crude fat tissues were washed twice to remove debris. 
Washed fat tissues collected were blotted on filter paper, 
weighed and cut in KRB-BSA solution into about 2 mm strips. 
Tissues were put into a plastic · 50-ml or lO-ml capped 
centrifuge-tubes. For every gram of fat tissue, 1.6 mg of 
collagenase and 2 ml KRB-BSA solution were added, 95% 02 5% 
C02 were then gassed on top of the tube. The mixture in the 
tube was incubated at 37·C for 2 h. Digested tissues were 
filtered through cheesecloth and washed with~ KRB-BSA solution. 
Washed adipocyte suspension was diluted with KRB-BSA solution. 
Purified adipocyte suspension were added into plastic microfuge 
tubes where Hr-TNF and LPS had been prepared. The mixture of 
the tube was incubated at 37°C with 95 % 02-5 % C02. After 
incubation for a certain period of time, equal volume (500ul) of 
10 % TCA was added to stop reaction. Tubes were centrifuged a~ 
10,000 x g or more for 20 minutes. Two hundred ul supernatant 
was removed from tubes for glycerol deter~ination. 
Both . glycerol and free fatty acid (FFA) are released from 
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the .udipocytes, but FFA will be reincorporated into t r i glycer i d e 
after reuptake and activation to acyl CoA derivative. The 
glycerol cannot be incorporated significantly after its release. 
Hence, lipolysis was determined by measuring the amount of 
glycerol released in our experiment. For glycerol 
determination, 50 ul of 1N H2S01 was added followed by 50 ul of 
50 mM sodium periodate (NaI04) to the supernatant. After 5 
minutes, 50 ul of 10 % sodium metabisulfite (Na2S20s) was added. 
After 5 minutes, 2 ml Chromotropic acid reagent was added. The 
tube contents were mixed and boiled for 30 minutes. Absorbance 
at 570nm (ODS70) were read. 
Effect of in vivo production of TNF on lipolysis, body 
temperature and body weight in rats 
Thirty mg zymosan was injected l.p. into each rat on day 
0, 125 ug LPS was injected i.v. on day 6. Rats were bled at the 
tail 2 h after the LPS injection, TNS titre was determined 
according to "materials and methods" in Chapter ' 3. The body 
temperature of rat was measured after the LPS injection by an 
electronic thermometer (YSI. Tele-thermometer). Fat cells were 
isolated and the lipolysis assay was carried out 1 day later. 




In our experiment, the effect of Hr-TNF on epinephrine 
stimulated lipolysis was investigated. Epinephrine 18 a 
lipolytic hormone which can activate the lipase and catalyze the 
degradation of triglyceride into glycerol and free fatty acid in 
adipocytes (Birnbaumer and Rodbell 1969). 
As shown in Fig. 9 . 1 , lipolysis was enhanced by 
epinephrine 1n a dose-dependent manner. Fig. 9.2 and Fig. 9.3 
showed that Hr-TNF at concentration as high as 5 ug/ml did not 
show any dose-dependent enhancement of lipolysis at 5 uM 
epinephrine. As shown in Fig. 9.4, addition of Hr-TNF (0.05 
ug/ml) did not affect significantly the epinephrine dose 
dependent mediated effect on lipolysis. However, the LPS (1000 
ug/ml) could suppress the rate of epinephrine stimulated 
lipolysis. In Fig. 9 • 5 , the result showed that 0.01 mg/ml Hr-
TNF did not affect the lipolytic effect of epinephrine 
significantly no matter whether 1.5 hour preincubation of Hr-TNF 
was used or not. However, 1000 ug/ml LPS could suppress the 
rate of epinephrine dose dependent mediated effect on lipolysis. 
I 
From Table 9.1, t~e combined application of zymosan and 
LPS or LPS only could induce TNF in rats. Fig.9.6 showed that 
both the in vivo production of TNF or the application of LPS 
only could stimulate the lipolysis. Fig.9.7 shows that TNF 
induction in zymosan primed rat by LPS could cause body 
temperature dropped below 35°C after about 1 h. Fig. 9.8 shows 
that LPS only could also induce the hypothermic effect in rat 
within 20 minutes. Fig.9.9 shows' that the in vivo production of 
TNF using zymosan and LPS could induce body weight loss. 
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Fig.9.l Effect of different doses of epinephrine on lipolysis in 
vitro. Different concentrations of epinephrine were incubated 
with isolated adipocytes for 1.5 h. The reaction was stopped by 
the addition of cold TeA and the amount of released glycerol was 




















0.000 0.005 :0.01 0 0.015 0.020 0.025 
TNF CONCENTRATION (ug/ml) 
Fig.9.2 Effect of different doses of Hr-TNF on lipolysis in 
vitro. Different concentrations ·of Hr-TNF were incubated with 
isolated adipocytes at 5.0 uM epinephrine for 1.5 h. The 
reaction was stopped by addition of cold TeA and the amount of 
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Fig.9.3 Effect of different doses of Hr-TNF on lipolysis in 
vitro. Different concentrations of Hr-TNF were incubated with 
isolated adipocytes at 5.0: uM epinephrine for 1.5 h. The 
reaction was stopped by addition of cold TeA and the amount of 
released glycerol was determined according to experimental. 
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Fig.9.4 Effect of LPS and Hr-TNF on the epinephrine dose 
dependent mediated lipolysis. Hr-TNF of 0.05 ug/ml and LPS of 
1000 ug/ml were incubated at various concentration of 
epinephrine with isolated adipocytes for 1.5 h. The reaction 
was stopped by the addition> of cold TeA and the amount of 
released glycerol was determined according to experimental. 
(O)Ep control; (e)Ep,Hr-TNF; (A)Ep,LPS. 
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Fig.9.5 Effect of LPS and Hr-TNF on the epinephrine dose 
dependent mediated lipolysis. Preincubations of the fat cells 
with Hr-TNF of 0.01 mg/ml were carried out for 1.5 h before the 
epinephrine was added. Hr-TNF of 0.01 mg/ml and LPS of 1000 
ug/ml were incubated at various concentrations of epinephrine 
with isolated adipocytes for 1.5 h. The reaction was stopped by 
the addition of cold TeA and the amount of released glycerol was 
determined according to experimental. (O)Ep control; (e)Ep,LPS; 












3427 ± 5693 
10,000 ± 120 
aOn day 0, 30 mg zymosan was injected i.p., 125 ug LPS was 
injected 1.V. on day 6. bRats were bled at tails 2 h after LPS 
injection. TNS titre was determined from pooled sera from 4 
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Fig.9.6 Effect of in vivo production of TNF and the application 
of LPS on the lipolysis in rats. For each rat, 30 mg zymosan 
was injected on day 0, 125 ug LPS was injected on day 6. On day 
7, fat cells were isolated and the lipolysis assay was carried 
out at 0.0 uM and 5.0 uM epinephrine (Ep). Bars are mean ± S.D~ 
for 3 experiments. The differences between the control and the 
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Fig.9.7 Effect of in vivo production of TNF on body temperature 
of rats. For each rat, 30 mg zymosan was injected i.p. on day 
0, 125 ug LPSwas injected i.v. on day 6. The body temperature 
was measured after LPS injection for 5 h. (. )No treatment; 
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Fig.9.S Effect of LPS only on the body temperature of rats. 125 
ug LPS was injected i.v. into each rat. The body temperature 
was measured after LPS injection for 1 h. (e)No treatment; 
(O)LPS. 
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Fig.9.9 Effect of in vivo production of TNF and the application 
of LPS on body weight of rabs. For each rat, 30 mg zymosan was 
injected i.p. on day 0, 12~ ug LPS was injected i.v. on day 5. 
The body weight of the Dats were determined on the indicated 
days. Bars are mean ± S.D. I for 3 experiments. The differences 
between the control and the groups of treatments were determined 
by Student's t test. *P<O.OOl . 
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Most prior studies of the metabolic effects of Hr-TNF have 
focused on 3T3-L1 cultured adipocytes and the expression o f 
enzyme for triglyceride accumulation (Pekala et al 1983). Hr-
TNF is several orders of magnitude more potent than IL-1, Hr-
IFN-~ or Hr-TNF-~ (lymphotoxin) in inhibiting the activity of 
lipoprotein lipase in 3T3-L1 cells, and has now been shown to 
stimulate lipolysis directly in these cells (Patton et al 1986, 
Porat 1989). In measuring lipolysis of adipocytes in our 
experiment, mouse adipocytes cannot be used because of the small 
amount of these cells in the body of mice. The 3T3-L1 cell is a 
mouse embryo fibroblasts differentiated adipocyte cell line 
whereas we are using normal Sprague-Dawley rat adipocytes in 
short term in vitro incubation. Our experiments indicated that 
Hr-TNF failed to show any stimulation of glycerol release from 
rat normal adipocytes. The result is consistent to that of 
other workers using Hr-TNF with adipocytes of Porton rat (Rofe 
et s1 1987) or CD starin rat (Kettelhut and Goldberg 1988). The 
treatment with Hr-TNF in vitro does not increase lipolysis no 
matter whether preincubation of Hr-TNF was used or not 
(Fig.9.5). Hr-TNF also does not affect the sensitivity of 
adipocytes to the lipolytic hormone, norepinephrine. These data 
indicate that Hr-TNF has no major effect on short-term 
metabolism in isolated normal adipocytes preparation in vitro. 
Although it is possible that the enzyme treatment by collagenase 
used to isolate the adipocytes might have affected the receptors 
for Hr-TNF, tpe adipocyte were still responsive to epinephrine 
suggesting such anon-specific effect is unlikely. Furthermore t 
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the amount of Hr-TNF (0.6 uM) used in present studies was far in 
excess of that required to demonstrate significant metabol i c 
effects in 3T3-L1 cells, 0.001 - 0.01 nM TNF has been used to 
test effect of Hr-TNF on 3T3-L1 cells (Patton et s1 1986). The 
Hr-TNF activity on lipolysis of rat normal adipocytes would have 
been present in our experiments. The different results of our 
experiments and the previous one using 3T3-L1 may due to the 
different type of adipocytes being used. 
On the other hand, the LPS could suppress lipolysis in 
adipose tissue in vitro (Fig.9.4, Fig.9.5). Many experiments 
indicated that both the LPS and TNF shared the common biological 
effects including the induction of cachexia, shock, the 
production of PGE2 and the inhibition of the activity of 
lipoprotein lipase (Old 1985). TNF has also been found in the 
serum of patients with septicemia (Waage et a1 1987). However, 
our result indicated that Hr-TNF failed to affect the rate of 
lipolysis but LPS could suppress the rate of lipolysis in vitro 
(Fig.9.4, Fig.9.5). It indicates that the biological effects of 
LPS and TNF are not completely consistent. Other report 
(Kettelhut and Goldberg 1988) also proved that when rats were 
administrated with endotoxin, they developed fever, and their 
muscle showed increased protein degradation and prostaglandin 
(PGE2) production. However, when fevers were induced by Hr-TNF, 
there was no change in muscle proteolysis or PGE2 production, 
. and no increase in basal or catecholamine-induced lipolysis was 
observed in adipose tissue. Also Hr-TNF addition in vitro did 
not enhance lipolysis in epididymal fat pads or proteolysis in 
soleus muscles (Kettelhut and Goldberg 1988). Thus, Hr-TNF 
treatment can induce fever without producing a catabolic state 
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similar to that induced by endotoxin. Hr-TNF cannot stimulate 
the lipolysis in vitro may indicate that the metabolic e ffects 
may be elicited by more complex incubation conditions. Hr-TNF 
probably does not act like a catabolic hormone, and its dire c t 
effects in this regard are probably minor in comparison with 
those of established hormones in determining cachexia. 
Moreover, further inv~stigation is needed to determine the 
specific properties of this highly purified and commercially 
available cytokine. 
In the experiment of in vivo production of TNF in rat 
using zymosan and LPS, TNS titre could be detected two hours 
after LPS injection. It indicated that TNF can also be induced 
in rats as in mice under this treatment. The result of 
lipolysis indicated that the production of TNF by zymosan and 
LPS could enhance the rate of lipolysis in vivo (Fig.5.6). 
Endotoxin had the 
(Fig.5.6). It is 
similar stimulating effect on lipolysis 
difficult to differentiate whether this 
suppression is mediated by TNF so produced or LPS itself basing 
on our experimental results. 
TNF production in zymosan-primed rat induced hypothermic 
effect after the LPS injection (Fig.9.7). However,LPS only 
could also induce hypothermic effect (Fig.9.8). Kettelhut et s1 
(1987) reported that Hr-TNF could induce hypothermic effect and 
lethality in male rats of CD strain. Some unidentified product 
of the cyclooxygenase was believed to reduce the body 
temperature (Kettelhutet s1 1987). Therefore, both Hr-TNF and 
LPS could probably induce hypothermic effect. It was difficult 
to differentiate whether this hypothermic effect was mediated by 
TNF so induced or LPS itself in our experiments. 
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Previous studies found that Hr-TNF· caused a reduct i on ln 
food consumption in rat (Kettelhut and Goldberg 1988). 
Therefore, the anorexia and catabolic state induced by TNF so 
produced accounted for the loss of the body weight in rats in 
our experiment. 
Our experiments for the determination of the effect of TNF 
on lipolysis in vivo has limitation. It is because the TNF so 
produced is induced by LPS. It is difficult to differentiate 
the effect is mediated by TNF itself or LPS side effect without 




CONCLUSION AND OUTLOOK 
Tumor necrosis factor (TNF) is a polypeptide which c an be 
produced in vivo by two steps according to Carswell et al 
(1975). The first step is known to activate t he 
reticuloendothelial system by priming agents (e.g. BCG 
(Carswell et sl 1975), C.parvum (Green et sl 1977». The second 
step is to elicit the release of TNF into serum from the TNF 
producing cells (e.g. rnacrophages (Zuckerman et sl 1989), 
natural killer cells (Beutler and Cerami 1987» by 
lipopolysaccharide (LPS). In our model, TNF was produced in 
zymosan primed Ehrlich ascites turnor (EAT) bearing mice by the 
challenge of LPS. Zymosan was believed to be an effective 
imrnunopotentiator because it can activate the lymphocytes and 
macrophages based on our results. TNF has been known to cause 
necrosis of certain turnors in vivo (Carswell et si 1975) and 
exert cytostatic and cytotoxic effects of certain turnors in 
vitro (Watanabe et ~l 1975, Haranaka and Satomi 1981). Anti-
tumor therapy by the induction of endogenous TNF by OK 432 in 
human has also been reported (Mikio et sl 1985). 
Nowadays, phase I and phase 11 clinical trials using human 
recombinant tumor necrosis factor (Hr-TNF) have been carried out 
to treat cancer patients (Frei and Spriggs et si 1989). 
, 
However, few advanced cancer patients treated with Hr-TNF gave 
objective beneficial responses. In our project, the in vivo 
production of TNF instead of the direct administration of Hr-TNF 
or murine recornbinant TNF was used to treat the EAT bearing 
mice. It is similar to the rationale of Coley in using Coley's 
toxin to treat cancer patients in 1893 (review see Old 1988). 
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Although the efficiency of our method using zymosan and LPS t o 
produce TNF in vivo to treat cancer awaits intensive 
investigations, this method may have many advantages over that 
of direct injection of Hr-TNF. Firstly, Hr-TNF is produced by 
cloning technology in Escherichia coli (Shirai et 81 1985). The 
Hr-TNF so produced is very expensive. On the other hand, the in 
vivo production of TNF using zymosan and LPS is much cheaper 
than using Hr-TNF. The preparation of zymosan for injection is 
easier than that of using bacteria and zymosan is less toxic 
than other bacteria such as BCG or Listeria monocytogenes. 
Secondly, Hr-TNF was reported to induce many systemic side-
effects after the administration in cancer patients (Spriggs et 
a1 1987). Although LPS has similar side effects as TNF in human 
or animals (Old, 1988), non-steroidal anti-inflammatory drug 
(NSAID)-sulindac and mannoheptulose can be used to protect the 
mice from endotoxin shock in our experiments. Moreover, natural 
TNF being induced in vivo by LPS may contain some other factors 
that act to prevent side effects (Haranaka 1988). Thirdly, the 
three dimensional structure may be different between natural and 
recombinant TNF and they may process different anti-tumor 
activities in vivo (Haranaka 1988). Moreover, Hr-TNF exert 
significant degrees of species preference in vivo or in vitro 
(Kramer et 81 1988). In conclusion, the method of in vivo 
production of TNF by zymosan and LPS developed in our studies 
provides a possible trial for the clinical applicati~n on cancer 
patient in the future. This method should be in a better 
position than Coley's approach since zymosan used in our method 





many limitations were found in our model. 
Firstly, LPS could induce many lethal side effects including the 
increase of lipolysis, hypoglycemia, weight loss and the 
hypothermic effect in our experimental model. Therefore, the 
methods to eliminate these side effects after LPS injection are 
valuable to investigate in the future. Secondly, TNF being 
induced just one time by single injection of zymosan and LPS 
cannot effectively cure the mice wheh they bear large burden of 
EAT. We found that the effectiveness of TNF so produced is 
better in mice when they bear little amount of EAT. 
One of the interesting finding in our studies is that the 
Hr-TNF could not enhance the lipolysis of normal rat adipocytes 
in vitro. Our results· are consistent to that of Rofe et 81 
(1987) and Kettelhut and Goldberg (1988)in in vitro studies. 
However, LPS was found to enhance lipolysis, induce hypothermic 
effect and weight loss in rat. Although, many experiments 
indicated that both the LPS and TNF shared the common biological 
effects including the induction of cachexia, shock, the 
production of PGE2 and inhibition of the activity of lipoprotein 
lipase in 3T3-Ll cell (Old 1985), our results indicated that the 
biological effects of LPS and TNF are not completely consistent. 
It is because Hr-TNF has been previously reported for the fail 
to affect the rate of lipolysis both in vitro (Rofe et 81 1987) 
and in vivo (Kettelhut and Goldberg 1988). On the other hand, 
LPS could suppress the rate of lipolysis in vitro and stimulate 
lipolysis in vivo in our experimental model. Further 
investigation is needed to determine the specific properties of 




The TNF titre determination in se r um and ascitic flu id was 
carried out using in vitro L929 cytotoxicity in my studies . 
Although the heat inactivation was carried out in these s ample s 
before the assay was done, we could not completely el imi nate 
other unknown factors or proteins in the serum which posses s the 
anti-tumor effect. For a more specific and accurate 
determination of TNF titre in body fluid, ELISA or RIA method 
must be used in the future. 
We found that the anti-turnor effect of in vivo production 
of TNF by zymosan and LPS is the best at the beginning state of 
the cancer disease (i.e. the number of EAT cells was very little 
in mice during the induction of TNF). The effectiveness of 
tumor killing effect of TNF at the early state of tumor 
development is higher than that at the advanced state of tumor 
development. Moreover, some EAT bearing mice will be completely 
cured and the lethality of mice after the injection of LPS will 
not be serious if the treatment carried out at the beginning 
stage of the cancer disease. Hence, it is recommended that TNF 
treatment is best applied during the beginning state of the 
cancer disease for the best clinical performance. Another point 
which must be paid attention on is that the amount of TNF being 
induced in mice must not be too high. It is because TNF is also 
a factor which causes cachecxia with many lethal side effects 
(Beutler 1988). Our results indicated that large amount of TNF 
so produced could induce a high lethality in EAT bearing mice. 
Therefore, optimal dose of zymosan and LPS should be used for 
the production of TNF in vivo. It is interesting that using 
this method the TNF produced in serum of EAT bearing mice was 
lower than that of normal mice. This may due to two possible 
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reasons. The first one is that the EAT cells may suppress the 
immune system in mice (review see Michael and George 1981) such 
that less TNF is induced. The second one is that the serum TNF 
being induced may pass into the peritoneal cavity such that the 
serum TNF titre become lower. The actual mechanism of this 
phenomenon is valuable to investigate. For example, the mice 
with the artificial induction of peritoneal fluid will be used 
to induce TNF for the investigation of the effect of the ascitic 
fluid on the TNF titre in serum. Moreover, the relationship 
between different EAT cell numbers in mice and the TNF titre in 
the ascitic fluid · or serum must also be investigated • 
The mechanisms of TNF in vivo cytotoxicity was not 
completely known. Many mechanisms have been suggested for the 
direct killing process of tumor cells by TNF, including free 
hydroxyl radicals generation (Yamauchi et 81 1989), release and 
activation of lysosomal enzyme in the tumor cells (Haranaka 
1988), fragmentation of cellular DNA in turnor cells (Berish et 
81 1989). In our studies, the suppression of EAT cell number 
was likely due to TNF direct cytotoxic effect because TNF could 
be found in ascitic fluid after the LPS injection in zymosan-
primed EAT bearing mice. This meant that the TNF in serum could 
pass into the peritoneal cavity in mice to kill the EAT cells. 
Our studies also indicate that in vivo production of TNF 
suppresses DNA and protein synthesis of EAT cells suggesting 
TNF's direct cytotoxic effect on growth of EAT cells. However, 
TNF being produced cannot affect the glucose uptake rate of the 
EAT in vivo. It may be because the EAT was induced an adaptive 
response for increasing the glucose transport activity because 
of hypoglycemia and low glucose level in ascitic fluid (Fung et 
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81 1986) in mice caused by lipopolysaccharide. The more 
detailed direct and indirect m~chanisms of the anti-tumor effect 
of in vivo production of TNF need further investigation. 
Combined treatment of Hr-TNF with other anti-cancer d rugs 
(e.g. MTX, 5-fluorouracil) or cytokines (e.g. IL-2, ~-IFN) may 
be carried out in clinical trial in the future. The trials of 
combined treatment of in vivo production of TNF and MTX, PALA, 
poly I'C or hyperthermia were investigated in our project in EAT 
bearing mice. From the results, we found that MTX, PALA and 
poly l·e are good candidates for the application in combined 
treatment with TNF. It is because all of them can give an 
additive effect on the suppression of the cell number during the 
day of cell counting and cure some of the EAT bearing mice alone 
or combined with in vivo production of TNF. Tne clinical 
results of the combined treatment of hyperthermia and the in 
vivo production of ' TNF can prolong the survival of EAT bearing 
mice. This method of using warm room for hyperthermia needs 
more modification to improve the clinical performance. 
Based on the results of our trials, the most effective 
treatment for the EAT bearing mice is to induce a little amount 
of TNF in EAT bearing mice at the beginning stage of the cancer 
disease. NSAlD and mannoheptulose are applied to protect the 
mice during the induction 




of suitable dose must be 
continuously applied after the inoculation of EAT. This 
combined treatment will offer a great opportunity to completely 
cure the EAT bearing mice and prolong the life of the mice with 
little side effects. However, the route and dosage for the 
application of the drugs must be further modified to improve the 
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effectiveness and clinical performance. 
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